Magnetic resonance spectroscopy of cancer metabolism and response to therapy

Radiation Research

Volumn 177, Issue 4, 2012, Pages 398-435

  McIntyre, Dominick J O ^a   Madhu, Basetti ^a   Lee, Shen Han ^a   Griffiths, John R ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANALYTIC METHOD; APOPTOSIS; BIOENERGY; CANCER CELL; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER TISSUE; CELL DEATH; EX VIVO STUDY; GLUCOSE METABOLISM; GLYCOLYSIS; HUMAN; HYPOXIA; IN VIVO STUDY; LIPID METABOLISM; METABOLISM; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PH; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE; TUMOR MODEL;

ADIPOSE TISSUE; ANIMALS; ANTINEOPLASTIC AGENTS; BODY WATER; CELL DEATH; CELL HYPOXIA; CLINICAL TRIALS AS TOPIC; DRUG MONITORING; ENERGY METABOLISM; FOURIER ANALYSIS; GLYCOLYSIS; HUMANS; HYDROGEN-ION CONCENTRATION; ISOTOPES; LIPID METABOLISM; MAGNETIC RESONANCE SPECTROSCOPY; MOLECULAR IMAGING; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; PROTONS; TREATMENT OUTCOME;

ANIMALIA;

EID: 84859747129     PISSN: 00337587     EISSN: 19385404     Source Type: Journal    
DOI: 10.1667/RR2903.1     Document Type: Review

References (341)

1. J. R. Griffiths, Are cancer cells acidic? Br J Cancer 64, 425-427 (1991).
2. W. Heindel, J. Bunke, S. Glathe, W. Steinbrich and L. Mollevanger, Combined H1 MR imaging and localized P31 spectroscopy of intracranial tumors in 43 patients. Journal of Computer Assisted Tomography 12, 907-916 (1988).
3. D. Artemov, Z. M. Bhujwalla and J. D. Glickson, In vivo selective measurement of (1-13C)-glucose metabolism in tumors by heteronuclear cross polarization. Magn Reson Med 33, 151-155 (1995).
4. D. Rivenzon-Segal, R. Margalit and H. Degani, Glycolysis as a metabolic marker in orthotopic breast cancer, monitored by in vivo C-13 MRS. American Journal of Physiology-Endocrinology and Metabolism 283, E623-E630 (2002).
5. J. H. Ardenkjaer-Larsen, B. Fridlund, A. Gram, G. Hansson, L. Hansson, M. H. Lerche, R. Servin, M. Thaning and K. Golman, Increase in signal-to-noise ratio of . 10,000 times in liquid-state NMR. Proc Natl Acad Sci USA 100, 10158-10163 (2003). (Pubitemid 37071849)
6. A. I. Hashim, X. Zhang, J. W. Wojtkowiak, G. V. Martinez and R. J. Gillies, Imaging pH and metastasis. NMR Biomed 24, 582-591 (2011).
7. S. E. Day, M. I. Kettunen, F. A. Gallagher, D. E. Hu, M. Lerche, J. Wolber, K. Golman, J. H. Ardenkjaer-Larsen and K. M. Brindle, Detecting tumor response to treatment using hyperpolarized C-13 magnetic resonance imaging and spectroscopy. Nature Medicine 13, 1382-1387 (2007). (Pubitemid 350073590)
8. M. Garwood and L. DelaBarre, The Return of the Frequency Sweep: Designing Adiabatic Pulses for Contemporary NMR. Journal of Magnetic Resonance 153, 155-177 (2001).
9. L. Barantin, A. Le Pape and S. Akoka, A new method for absolute quantitation of MRS metabolites. Magn Reson Med 38, 179-182 (1997). (Pubitemid 27328242)
10. A. Naressi, C. Couturier, J. M. Devos, M. Janssen, C. Mangeat, R. de Beer and D. Graveron-Demilly, Java-based graphical user interface for the MRUI quantitation package. MAGMA. 12, 141-152 (2001). (Pubitemid 32510133)
11. L. Vanhamme, A. van den Boogaart and S. Van Huffel, Improved method for accurate and efficient quantification of MRS data with use of prior knowledge. Journal of Magnetic Resonance 129, 35-43 (1997). (Pubitemid 127454051)
12. S. W. Provencher, Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 30, 672-679 (1993). (Pubitemid 23360802)
13. J. E. Le Belle, N. G. Harris, S. R. Williams and K. K. Bhakoo, A comparison of cell and tissue extraction techniques using highresolution 1H-NMR spectroscopy. NMR Biomed 15, 37-44 (2002). (Pubitemid 34177166)
14. R. K. Tyagi, A. Azrad, H. Degani and Y. Salomon, Simultaneous extraction of cellular lipids and water-soluble metabolites: evaluation by NMR spectroscopy. Magn Reson Med 35, 194-200 (1996). (Pubitemid 26044386)
15. A. B. E. R. Andrew, R. G. Eades Nuclear magnetic resonance spectra from a crystal rotated at high speed. Nature 182, 1659 (1958).
16. R. Haberkorn, J. Herzfeld and R. Griffin, High resolution phosphorus-31 and carbon-13 nuclear magnetic resonance spectra of unsonicated model membranes. J Am Chem Soc 100, 1296-1298 (1978).
17. J. D. Gross, P. R. Costa, J. P. Dubacq, D. E. Warschawski, P. N. Lirsac, P. F. Devaux and R. G. Griffin, Multidimensional NMR in lipid systems. Coherence transfer through J couplings under MAS. J Magn Reson B 106, 187-190 (1995).
18. J. H. Davis, M. Auger and R. S. Hodges, High resolution 1H nuclear magnetic resonance of a transmembrane peptide. Biophys J 69, 1917-1932 (1995).
19. L. L. Cheng, M. J. Ma, L. Becerra, T. Ptak, I. Tracey, A. Lackner and R. G. Gonzalez, Quantitative neuropathology by high resolution magic angle spinning proton magnetic resonance spectroscopy. Proc Natl Acad Sci USA 94, 6408-6413 (1997). (Pubitemid 27270698)
20. L. L. Cheng, I. W. Chang, D. N. Louis and R. G. Gonzalez, Correlation of high-resolution magic angle spinning proton magnetic resonance spectroscopy with histopathology of intact human brain tumor specimens. Cancer Res 58, 1825-1832 (1998). (Pubitemid 28217454)
21. L. L. Cheng, I. W. Chang, B. L. Smith and R. G. Gonzalez, Evaluating human breast ductal carcinomas with high-resolution magic-angle spinning proton magnetic resonance spectroscopy. J Magn Reson 135, 194-202 (1998). (Pubitemid 128450704)
22. L. L. Cheng, C. Wu, M. R. Smith and R. G. Gonzalez, Nondestructive quantitation of spermine in human prostate tissue samples using HRMAS 1H NMR spectroscopy at 9.4 T. FEBS Lett 494, 112-116 (2001). (Pubitemid 32289382)
23. K. K. Lehtimaki, P. K. Valonen, J. L. Griffin, T. H. Vaisanen, O. H. J. Grohn, M. I. Kettunen, J. Vepsalainen, S. Yla-Herttuala, J. Nicholson and R. A. Kauppinen, Metabolite changes in BT4C rat gliomas undergoing ganciclovir-thymidine kinase gene therapyinduced programmed cell death as studied by H-1 NMR spectroscopy in vivo, ex vivo, and in vitro. Journal of Biological Chemistry 278, 45915-45923 (2003). (Pubitemid 37432737)
24. P. K. Valonen, J. L. Griffin, K. K. Lehtimaki, T. Liimatainen, J. K. Nicholson, O. H. Grohn and R. A. Kauppinen, High-resolution magic-angle-spinning 1H NMR spectroscopy reveals different responses in choline-containing metabolites upon gene therapyinduced programmed cell death in rat brain glioma. NMR Biomed 18, 252-259 (2005). (Pubitemid 40936445)
25. B. Madhu, J. C. Waterton, J. R. Griffiths, A. J. Ryan and S. P. Robinson, The response of RIF-1 fibrosarcomas to the vasculardisrupting agent ZD6126 assessed by in vivo and ex vivo 1H magnetic resonance spectroscopy. Neoplasia 8, 560-567 (2006). (Pubitemid 44061311)
26. K. S. Opstad, B. A. Bell, J. R. Griffiths and F. A. Howe, Toward accurate quantification of metabolites, lipids, and macromolecules in HRMAS spectra of human brain tumor biopsies using LCModel. Magn Reson Med 60, 1237-1242 (2008).
27. H. Rabeson, F. Fauvelle, G. Testylier, A. Foquin, P. Carpentier, F. Dorandeu, D. van Ormondt and D. Graveron-Demilly, Quantitation with QUEST of brain HRMAS-NMR signals: application to metabolic disorders in experimental epileptic seizures. Magn Reson Med 59, 1266-1273 (2008). (Pubitemid 351813254)
28. H. Ratiney, M. J. Albers, H. Rabeson and J. Kurhanewicz, Semiparametric time-domain quantification of HR-MAS data from prostate tissue. NMR Biomed 23, 1146-1157 (2010).
29. M. Wilson, G. Reynolds, R. A. Kauppinen, T. N. Arvanitis and A. C. Peet, A constrained least-squares approach to the automated quantitation of in vivo (1)H magnetic resonance spectroscopy data. Magn Reson Med 65, 1-12 (2011).
30. O. Risa, T. M. Melo and U. Sonnewald, Quantification of amounts and (13)C content of metabolites in brain tissue using high-resolution magic angle spinning (13)C NMR spectroscopy. NMR Biomed 22, 266-271 (2009).
31. S. Moestue, B. Sitter, T. F. Bathen, M. B. Tessem and I. S. Gribbestad, HR MAS MR spectroscopy in metabolic characterization of cancer. Curr Top Med Chem 11, 2-26 (2010).
32. J. L. Griffin, C. Blenkiron, P. K. Valonen, C. Caldas and R. A. Kauppinen, High-resolution magic angle spinning 1H NMR spectroscopy and reverse transcription-PCR analysis of apoptosis in a rat glioma. Anal Chem 78, 1546-1552 (2006). (Pubitemid 43346292)
33. E. M. DeFeo and L. L. Cheng, Characterizing human cancer metabolomics with ex vivo 1H HRMAS MRS. Technol Cancer Res Treat 9, 381-391 (2010).
34. G. S. Payne, H. Troy, S. J. Vaidya, J. R. Griffiths, M. O. Leach and Y. L. Chung, Evaluation of 31P high-resolution magic angle spinning of intact tissue samples. NMR Biomed 19, 593-598 (2006).
35. M. C. Martinez-Bisbal, L. Marti-Bonmati, J. Piquer, A. Revert, P. Ferrer, J. L. Llacer, M. Piotto, O. Assemat and B. Celda, 1H and 13C HR-MAS spectroscopy of intact biopsy samples ex vivo and in vivo 1H MRS study of human high grade gliomas. NMR Biomed 17, 191-205 (2004). (Pubitemid 39089246)
36. K. S. Opstad, A. J. Wright, B. A. Bell, J. R. Griffiths and F. A. Howe, Correlations between in vivo (1)H MRS and ex vivo (1)H HRMAS metabolite measurements in adult human gliomas. J Magn Reson Imaging 31, 289-297 (2010).
37. A. A. Tzika, L. Astrakas, H. Cao, D. Mintzopoulos, O. C. Andronesi, M. Mindrinos, J. Zhang, L. G. Rahme, K. D. Blekas, et al., Combination of high-resolution magic angle spinning proton magnetic resonance spectroscopy and microscale genomics to type brain tumor biopsies. Int J Mol Med 20, 199-208 (2007).
38. O. Warburg, The Metabolism of Tumors. Constable, London, 1930.
39. R. J. DeBerardinis, J. J. Lum, G. Hatzivassiliou and C. B. Thompson, The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 7, 11-20 (2008).
40. G. Kroemer and J. Pouyssegur, Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 13, 472-482 (2008). (Pubitemid 351766797)
41. J. W. Kim, I. Tchernyshyov, G. L. Semenza and C. V. Dang, HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab 3, 177-185 (2006).
42. I. Papandreou, R. A. Cairns, L. Fontana, A. L. Lim and N. C. Denko, HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab 3, 187-197 (2006).
43. M. Terpstra, R. Gruetter, W. B. High, M. Mescher, L. DelaBarre, H. Merkle and M. Garwood, Lactate turnover in rat glioma measured by in vivo nuclear magnetic resonance spectroscopy. Cancer Res 58, 5083-5088 (1998). (Pubitemid 28521166)
44. M. Terpstra, W. B. High, Y. Luo, R. A. de Graaf, H. Merkle and M. Garwood, Relationships among lactate concentration, blood flow and histopathologic profiles in rat C6 glioma. NMR Biomed 9, 185-194 (1996). (Pubitemid 27266176)
45. D. Ott, J. Hennig and T. Ernst, Human brain tumors: assessment with in vivo proton MR spectroscopy. Radiology 186, 745-752 (1993). (Pubitemid 23073517)
46. H. Kugel, W. Heindel, R. I. Ernestus, J. Bunke, R. du Mesnil and G. Friedmann, Human brain tumors: spectral patterns detected with localized H-1 MR spectroscopy. Radiology 183, 701-709 (1992).
47. A. K. Bouzier, R. Goodwin, F. M. de Gannes, H. Valeins, P. Voisin, P. Canioni and M. Merle, Compartmentation of lactate and glucose metabolism in C6 glioma cells. A 13c and 1H NMR study. J Biol Chem 273, 27162-27169 (1998). (Pubitemid 28500424)
48. D. Artemov, Z. M. Bhujwalla, U. Pilatus and J. D. Glickson, Two-compartment model for determination of glycolytic rates of solid tumors by in vivo 13C NMR spectroscopy. NMR Biomed 11, 395-404 (1998). (Pubitemid 29031849)
49. F. U. Nielsen, P. Daugaard, L. Bentzen, H. Stodkilde-Jorgensen, J. Overgaard, M. R. Horsman and R. J. Maxwell, Effect of changing tumor oxygenation on glycolytic metabolism in a murine C3H mammary carcinoma assessed by in vivo nuclear magnetic resonance spectroscopy. Cancer Res 61, 5318-5325 (2001). (Pubitemid 32681571)
50. G. Migneco, D. Whitaker-Menezes, B. Chiavarina, R. Castello-Cros, S. Pavlides, R. G. Pestell, A. Fatatis, N. Flomenberg, A. Tsirigos, et al., Glycolytic cancer associated fibroblasts promote breast cancer tumor growth, without a measurable increase in angiogenesis: evidence for stromal-epithelial metabolic coupling. Cell Cycle 9, 2412-2422 (2010).
51. S. Pavlides, D. Whitaker-Menezes, R. Castello-Cros, N. Flomenberg, A. K. Witkiewicz, P. G. Frank, M. C. Casimiro, C. Wang, P. Fortina, et al., The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell Cycle 8, 3984-4001 (2009).
52. C. M. Cham and T. F. Gajewski, Glucose availability regulates IFN-gamma production and p70S6 kinase activation in CD8 + effector T cells. J Immunol 174, 4670-4677 (2005).
53. K. A. Frauwirth and C. B. Thompson, Regulation of T lymphocyte metabolism. J Immunol 172, 4661-4665 (2004). (Pubitemid 38456383)
54. K. Golman, R. I. Zandt, M. Lerche, R. Pehrson and J. H. Ardenkjaer-Larsen, Metabolic imaging by hyperpolarized 13C magnetic resonance imaging for in vivo tumor diagnosis. Cancer Res 66, 10855-10860 (2006). (Pubitemid 44876982)
55. M. J. Albers, R. Bok, A. P. Chen, C. H. Cunningham, M. L. Zierhut, V. Y. Zhang, S. J. Kohler, J. Tropp, R. E. Hurd, et al., Hyperpolarized 13C lactate, pyruvate, and alanine: noninvasive biomarkers for prostate cancer detection and grading. Cancer Res 68, 8607-8615 (2008).
56. I. Park, P. E. Larson, M. L. Zierhut, S. Hu, R. Bok, T. Ozawa, J. Kurhanewicz, D. B. Vigneron, S. R. Vandenberg, et al., Hyperpolarized 13C magnetic resonance metabolic imaging: application to brain tumors. Neuro-Oncology 12, 133-144 (2010).
57. V. Collet, D. Carrez, A. Croisy and J. L. Dimicoli, Effect of methionine on glycolysis in tumor cells: in vivo and in vitro NMR studies. NMR Biomed 9, 47-52 (1996). (Pubitemid 26352492)
58. S. Telang, A. N. Lane, K. K. Nelson, S. Arumugam and J. Chesney, The oncoprotein H-RasV12 increases mitochondrial metabolism. Mol Cancer 6, 77 (2007).
59. R. J. DeBerardinis, A. Mancuso, E. Daikhin, I. Nissim, M. Yudkoff, S. Wehrli and C. B. Thompson, Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci USA 104, 19345-19350 (2007).
60. T. W. Fan, M. Kucia, K. Jankowski, R. M. Higashi, J. Ratajczak, M. Z. Ratajczak and A. N. Lane, Rhabdomyosarcoma cells show an energy producing anabolic metabolic phenotype compared with primary myocytes. Mol Cancer 7, 79 (2008).
61. T. W. Fan, A. N. Lane, R. M. Higashi, M. A. Farag, H. Gao, M. Bousamra and D. M. Miller, Altered regulation of metabolic pathways in human lung cancer discerned by (13)C stable isotope-resolved metabolomics (SIRM). Mol Cancer 8, 41 (2009).
62. J. R. Griffiths, A. N. Stevens, R. A. Iles, R. E. Gordon and D. Shaw, 31P-NMR investigation of solid tumors in the living rat. Biosci Rep 1, 319-325 (1981).
63. W. T. Evanochko, T. C. Ng, J. D. Glickson, J. R. Durant and T. H. Corbett, Human tumors as examined by in vivo 31P NMR in athymic mice. Biochem Biophys Res Commun 109, 1346-1352 (1982). (Pubitemid 13110277)
64. J. R. Griffiths, E. Cady, R. H. Edwards, V. R. McCready, D. R. Wilkie and E. Wiltshaw, 31P-NMR studies of a human tumor in situ. Lancet 1, 1435-1436 (1983). (Pubitemid 13053320)
65. J. D. de Certaines, V. A. Larsen, F. Podo, G. Carpinelli, O. Briot and O. Henriksen, In vivo 31P MRS of experimental tumors. NMR Biomed 6, 345-365 (1993). (Pubitemid 2031145)
66. W. Negendank, Studies of human tumors by MRS: a review. NMR Biomed 5, 303-324 (1992).
67. F. Arias-Mendoza, K. Zakian, A. Schwartz, F. A. Howe, J. A. Koutcher, M. O. Leach, J. R. Griffiths, A. Heerschap, J. D. Glickson, et al., Methodological standardization for a multiinstitutional in vivo trial of localized 31P MR spectroscopy in human cancer research. In vitro and normal volunteer studies. NMR Biomed 17, 382-391 (2004). (Pubitemid 39335176)
68. F. Arias-Mendoza, G. S. Payne, K. Zakian, M. Stubbs, J. G. Cruz-Lobo, A. J. Schwarz, A. Shukla-Dave, F. Howe, N. R. Maisey, et al., Treatment response predictor using 31P MRS for chop and R-chop therapy in diffuse large B-cell lymphoma. Annals of Oncology 19, 147-147 (2008).
69. F. Arias-Mendoza, G. S. Payne, K. L. Zakian, A. J. Schwarz, M. Stubbs, R. Stoyanova, D. Ballon, F. A. Howe, J. A. Koutcher, et al., In vivo 31P MR spectral patterns and reproducibility in cancer patients studied in a multi-institutional trial. NMR Biomed 19, 504-512 (2006). (Pubitemid 43997769)
70. F. Arias-Mendoza, M. O. Leach, J. A. Koutcher, J. R. Griffiths, A. Heerschap, J. D. Glickson, O. A. O'Connor, T. R. Brown and M. R. A. C. Cooperat Grp, Prediction of treatment response in subtypes of non-Hodgkin's lymphoma by in vivo P-31 MR spectroscopy before treatment. Journal of Clinical Oncology 27, 8565 (2009).
71. F. Arias-Mendoza, M. R. Smith and T. R. Brown, Predicting treatment response in non-Hodgkin's lymphoma from the pretreatment tumor content of phosphoethanolamine plus phosphocholine. Academic Radiology 11, 368-376 (2004). (Pubitemid 38405365)
72. R. Kalra, K. E. Wade, L. Hands, P. Styles, R. Camplejohn, M. Greenall, G. E. Adams, A. L. Harris and G. K. Radda, Phosphomonoester is associated with proliferation in human breast cancer: a 31P MRS study. Br J Cancer 67, 1145-1153 (1993). (Pubitemid 23147520)
73. X. Maldonado, J. Alonso, J. Giralt, M. G. Cucurella, J. M. del Campo, A. Rovira, E. Felip, J. Capellades, E. Grivé, et al., 31Phosphorus magnetic resonance spectroscopy in the assessment of head and neck tumors. Int J Radiat Oncol Biol Phys 40, 309-312 (1998). (Pubitemid 28114373)
74. M. G. Vander Heiden, L. C. Cantley and C. B. Thompson, Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324, 1029-1033 (2009).
75. S. J. Li, J. P. Wehrle, S. S. Rajan, R. G. Steen, J. D. Glickson and J. Hilton, Response of radiation-induced fibrosarcoma-1 in mice to cyclophosphamide monitored by in vivo 31P nuclear magnetic resonance spectroscopy. Cancer Res 48, 4736-4742 (1988).
76. P. G. Okunieff, J. A. Koutcher, L. Gerweck, E. McFarland, B. Hitzig, M. Urano, T. Brady, L. Neuringer and H. D. Suit, Tumor size dependent changes in a murine fibrosarcoma: use of in vivo 31P NMR for non-invasive evaluation of tumor metabolic status. Int J Radiat Oncol Biol Phys 12, 793-799 (1986). (Pubitemid 16033478)
77. R. F. Kallman, The phenomenon of reoxygenation and its implications for fractionated radiotherapy. Radiology 105, 135-142 (1972).
78. G. M. Tozer and J. R. Griffiths, The contribution made by cell death and oxygenation to 31P MRS observations of tumor energy metabolism. NMR Biomed 5, 279-289 (1992).
79. D. R. Olsen and E. K. Rofstad, Monitoring of tumor reoxygenation following irradiation by 31P magnetic resonance spectroscopy: an experimental study of human melanoma xenografts. Radiother Oncol 52, 261-267 (1999). (Pubitemid 29486647)
80. H. Lyng, D. R. Olsen, T. E. Southon and E. K. Rofstad, 31Pnuclear magnetic resonance spectroscopy in vivo of six human melanoma xenograft lines: tumor bioenergetic status and blood supply. Br J Cancer 68, 1061-1070 (1993).
81. J. A. Koutcher, A. A. Alfieri, M. L. Devitt, J. G. Rhee, A. B. Kornblith, U. Mahmood, T. E. Merchant and D. Cowburn, Quantitative changes in tumor metabolism, partial pressure of oxygen, and radiobiological oxygenation status postradiation. Cancer Res 52, 4620-4627 (1992).
82. X. L. Zu and M. Guppy, Cancer metabolism: facts, fantasy, and fiction. Biochem Biophys Res Commun 313, 459-465 (2004). (Pubitemid 38021849)
83. P. Vaupel, F. Kallinowski and P. Okunieff, Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 49, 6449-6465 (1989). (Pubitemid 20008770)
84. M. Guppy, P. Leedman, X. Zu and V. Russell, Contribution by different fuels and metabolic pathways to the total ATP turnover of proliferating MCF-7 breast cancer cells. Biochem J 364, 309-315 (2002). (Pubitemid 34538975)
85. M. Stubbs and J. R. Griffiths, The altered metabolism of tumors: HIF-1 and its role in the Warburg effect. Adv Enzyme Regul 50, 44-55 (2010).
86. H. Schmidt, W. Siems, M. Muller, R. Dumdey and S. M. Rapoport, ATP-producing and consuming processes of Ehrlich mouse ascites tumor cells in proliferating and resting phases. Exp Cell Res 194, 122-127 (1991). (Pubitemid 121006256)
87. D. W. Parsons, S. Jones, X. Zhang, J. C. Lin, R. J. Leary, P. Angenendt, P. Mankoo, H. Carter, I. M. Siu, et al., An integrated genomic analysis of human glioblastoma multiforme. Science 321, 1807-1812 (2008).
88. L. Dang, D. W. White, S. Gross, B. D. Bennett, M. A. Bittinger, E. M. Driggers, V. R. Fantin, H. G. Jang, S. Jin, et al., Cancerassociated IDH1 mutations produce 2-hydroxyglutarate. Nature 462, 739-744 (2009).
89. A. K. Bouzier, B. Quesson, H. Valeins, P. Canioni and M. Merle, [1-(13)C]glucose metabolism in the tumoral and nontumoral cerebral tissue of a glioma-bearing rat. J Neurochem 72, 2445-2455 (1999). (Pubitemid 29242195)
90. J. C. Portais, R. Schuster, M. Merle and P. Canioni, Metabolic flux determination in C6 glioma cells using carbon-13 distribution upon [1-13C]glucose incubation. Eur J Biochem 217, 457-468 (1993). (Pubitemid 23305318)
91. M. A. Schroeder, H. J. Atherton, D. R. Ball, M. A. Cole, L. C. Heather, J. L. Griffin, K. Clarke, G. K. Radda and D. J. Tyler, Real-time assessment of Krebs cycle metabolism using hyperpolarized 13C magnetic resonance spectroscopy. FASEB J 23, 2529-2538 (2009).
92. F. Podo, Tumor phospholipid metabolism. NMR Biomed 12, 413-439 (1999).
93. E. O. Aboagye and Z. M. Bhujwalla, Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. Cancer Res 59, 80-84 (1999). (Pubitemid 29062961)
94. E. Iorio, D. Mezzanzanica, P. Alberti, F. Spadaro, C. Ramoni, S. D'Ascenzo, D. Millimaggi, A. Pavan, V. Dolo, et al., Alterations of choline phospholipid metabolism in ovarian tumor progression. Cancer Res 65, 9369-9376 (2005). (Pubitemid 41508005)
95. J. L. Griffin and R. A. Kauppinen, A metabolomics perspective of human brain tumors. FEBS J 274, 1132-1139 (2007).
96. C. F. Santos, J. Kurhanewicz, Z. L. Tabatabai, J. P. Simko, K. R. Keshari, A. Gbegnon, R. D. Santos, S. Federman, K. Shinohara, et al., Metabolic, pathologic, and genetic analysis of prostate tissues: quantitative evaluation of histopathologic and mRNA integrity after HR-MAS spectroscopy. NMR Biomed 23, 391-398 (2010).
97. N. R. Jagannathan, M. Kumar, V. Seenu, O. Coshic, S. N. Dwivedi, P. K. Julka, A. Srivastava and G. K. Rath, Evaluation of total choline from in-vivo volume localized proton MR spectroscopy and its response to neoadjuvant chemotherapy in locally advanced breast cancer. Br J Cancer 84, 1016-1022 (2001). (Pubitemid 32448495)
98. P. J. Bolan, S. Meisamy, E. H. Baker, J. Lin, T. Emory, M. Nelson, L. I. Everson, D. Yee and M. Garwood, In vivo quantification of choline compounds in the breast with 1H MR spectroscopy. Magn Reson Med 50, 1134-1143 (2003). (Pubitemid 37494015)
99. S. Meisamy, P. J. Bolan, E. H. Baker, R. L. Bliss, E. Gulbahce, L. I. Everson, M. T. Nelson, T. H. Emory, T. M. Tuttle, et al., Neoadjuvant chemotherapy of locally advanced breast cancer: Predicting response with in vivo H-1 MR spectroscopy-A pilot study. Radiology 233, 424-431 (2004). (Pubitemid 39423801)
100. A. Heerschap, G. J. Jager, M. van der Graaf, J. O. Barentsz, J. J. de la Rosette, G. O. Oosterhof, E. T. Ruijter and S. H. Ruijs, In vivo proton MR spectroscopy reveals altered metabolite content in malignant prostate tissue. Anticancer Res 17, 1455-1460 (1997). (Pubitemid 27257633)
101. J. M. Star-Lack, E. Adalsteinsson, M. F. Adam, D. J. Terris, H. A. Pinto, J. M. Brown and D. M. Spielman, In vivo 1H MR spectroscopy of human head and neck lymph node metastasis and comparison with oxygen tension measurements. AJNR Am J Neuroradiol 21, 183-193 (2000). (Pubitemid 30225850)
102. C. W. Mun, J. Y. Cho, W. J. Shin, K. S. Choi, C. K. Eun, S. S. Cha, J. Lee, Y. I. Yang, S. H. Nam, et al., Ex vivo proton MR spectroscopy (1H-MRS) for evaluation of human gastric carcinoma. Magn Reson Imaging 22, 861-870 (2004). (Pubitemid 38962324)
103. M. J. Albers, M. D. Krieger, I. Gonzalez-Gomez, F. H. Gilles, J. G. McComb, M. D. Nelson, Jr. and S. Bluml, Proton-decoupled 31P MRS in untreated pediatric brain tumors. Magn Reson Med 53, 22-29 (2005). (Pubitemid 40110473)
104. R. M. Bourne, P. Stanwell, J. R. Stretch, R. A. Scolyer, J. F. Thompson, C. E. Mountford and C. L. Lean, In vivo and ex vivo proton MR spectroscopy of primary and secondary melanoma. Eur J Radiol 53, 506-513 (2005). (Pubitemid 40312143)
105. A. D. King, D. K. Yeung, A. T. Ahuja, G. M. Tse, A. B. Chan, S. S. Lam and A. C. van Hasselt, In vivo 1H MR spectroscopy of thyroid carcinoma. Eur J Radiol 54, 112-117 (2005).
106. R. V. Simoes, A. Martinez-Aranda, B. Martin, S. Cerdan, A. Sierra and C. Arus, Preliminary characterization of an experimental breast cancer cells brain metastasis mouse model by MRI/MRS. MAGMA 21, 237-249 (2008).
107. F. Podo, S. Canevari, R. Canese, M. E. Pisanu, A. Ricci and E. Iorio, MR evaluation of response to targeted treatment in cancer cells. NMR Biomed (2011).
108. S. S. Gill, D. G. Thomas, N. Van Bruggen, D. G. Gadian, C. J. Peden, J. D. Bell, I. J. Cox, D. K. Menon, R. A. Iles, et al., Proton MR spectroscopy of intracranial tumors: in vivo and in vitro studies. J Comput Assist Tomogr 14, 497-504 (1990). (Pubitemid 20217153)
109. C. Remy, M. Von Kienlin, S. Lotito, A. Francois, A. L. Benabid and M. Decorps, In vivo 1H NMR spectroscopy of an intracerebral glioma in the rat. Magn Reson Med 9, 395-401 (1989). (Pubitemid 19088102)
110. R. J. Gillies, J. A. Barry and B. D. Ross, In vitro and in vivo 13C and 31P NMR analyses of phosphocholine metabolism in rat glioma cells. Magn Reson Med 32, 310-318 (1994). (Pubitemid 24274909)
111. B. L. Miller, L. Chang, R. Booth, T. Ernst, M. Cornford, D. Nikas, D. McBride and D. J. Jenden, In vivo 1H MRS choline: correlation with in vitro chemistry/histology. Life Sci 58, 1929-1935 (1996).
112. D. Morvan, A. Demidem, J. Papon and J. C. Madelmont, Quantitative HRMAS proton total correlation spectroscopy applied to cultured melanoma cells treated by chloroethyl nitrosourea: demonstration of phospholipid metabolism alterations. Magn Reson Med 49, 241-248 (2003). (Pubitemid 36159860)
113. Y. Kinoshita and A. Yokota, Absolute concentrations of metabolites in human brain tumors using in vitro proton magnetic resonance spectroscopy. NMR Biomed 10, 2-12 (1997). (Pubitemid 27346611)
114. B. F. Jordan, K. Black, I. F. Robey, M. Runquist, G. Powis and R. J. Gillies, Metabolite changes in HT-29 xenograft tumors following HIF-1 alpha inhibition with PX-478 as studied by MR spectroscopy in vivo and ex vivo. NMR Biomed 18, 430-439 (2005). (Pubitemid 41646184)
115. J. Ross, A. M. Najjar, M. Sankaranarayanapillai, W. P. Tong, K. Kaluarachchi and S. M. Ronen, Fatty acid synthase inhibition results in a magnetic resonance-detectable drop in phosphocholine. Mol Cancer Ther 7, 2556-2565 (2008).
116. D. Koul, R. J. Shen, Y. W. Kim, Y. Kondo, Y. L. Lu, J. Bankson, S. M. Ronen, D. L. Kirkpatrick, G. Powis and W. K. A. Yung, Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma. Neuro-Oncology 12, 559-569 (2010).
117. A. T. Baykal, M. R. Jain and H. Li, Aberrant regulation of choline metabolism by mitochondrial electron transport system inhibition in neuroblastoma cells. Metabolomics 4, 347-356 (2008).
118. K. Glunde, V. Raman, N. Mori and Z. M. Bhujwalla, RNA interference-mediated choline kinase suppression in breast cancer cells induces differentiation and reduces proliferation. Cancer Res 65, 11034-11043 (2005). (Pubitemid 41713374)
119. B. Krishnamachary, K. Glunde, F. Wildes, N. Mori, T. Takagi, V. Raman and Z. M. Bhujwalla, Noninvasive detection of lentiviralmediated choline kinase targeting in a human breast cancer xenograft. Cancer Res 69, 3464-3471 (2009).
120. N. M. Al-Saffar, H. Troy, A. Ramirez de Molina, L. E. Jackson, B. Madhu, J. R. Griffiths, M. O. Leach, P. Workman, J. C. Lacal, et al., Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of the choline kinase inhibitor MN58b in human carcinoma models. Cancer Res 66, 427-434 (2006). (Pubitemid 43166051)
121. P. E. Sijens, M. J. van den Bent, P. J. Nowak, P. van Dijk and M. Oudkerk, 1H chemical shift imaging reveals loss of brain tumor choline signal after administration of Gd-contrast. Magn Reson Med 37, 222-225 (1997). (Pubitemid 27045394)
122. A. P. Lin and B. D. Ross, Short-echo time proton MR spectroscopy in the presence of gadolinium. J Comput Assist Tomogr 25, 705-712 (2001). (Pubitemid 32861693)
123. B. Madhu, S. P. Robinson, F. A. Howe and J. R. Griffiths, Effect of Gd-DTPA-BMA on choline signals of HT29 tumors detected by in vivo 1H MRS. J Magn Reson Imaging 28, 1201-1208 (2008).
124. R. E. Lenkinski, X. Wang, M. Elian and S. N. Goldberg, Interaction of gadolinium-based MR contrast agents with choline: implications for MR spectroscopy (MRS) of the breast. Magn Reson Med 61, 1286-1292 (2009).
125. D. L. Morse, N. Raghunand, P. Sadarangani, S. Murthi, C. Job, S. Day, C. Howison and R. J. Gillies, Response of choline metabolites to docetaxel therapy is quantified in vivo by localized (31)P MRS of human breast cancer xenografts and in vitro by high-resolution (31)P NMR spectroscopy of cell extracts. Magn Reson Med 58, 270-280 (2007). (Pubitemid 47267644)
126. L. R. Jensen, E. M. Huuse, T. F. Bathen, P. E. Goa, A. M. Bofin, T. B. Pedersen, S. Lundgren and I. S. Gribbestad, Assessment of early docetaxel response in an experimental model of human breast cancer using DCE-MRI, ex vivo HR MAS, and in vivo 1H MRS. NMR Biomed 23, 56-65 (2010).
127. J. M. Hakumaki, H. Poptani, A. M. Sandmair, S. Yla-Herttuala and R. A. Kauppinen, 1H MRS detects polyunsaturated fatty acid accumulation during gene therapy of glioma: implications for the in vivo detection of apoptosis. Nat Med 5, 1323-1327 (1999). (Pubitemid 29535613)
128. C. E. Mountford and L. C. Wright, Organization of lipids in the plasma membranes of malignant and stimulated cells: a new model. Trends Biochem Sci 13, 172-177 (1988).
129. C. Remy, N. Fouilhe, I. Barba, E. Sam-Lai, H. Lahrech, M. G. Cucurella, M. Izquierdo, A. Moreno, A. Ziegler, et al., Evidence that mobile lipids detected in rat brain glioma by 1H nuclear magnetic resonance correspond to lipid droplets. Cancer Res 57, 407-414 (1997). (Pubitemid 27081656)
130. K. S. Opstad, B. A. Bell, J. R. Griffiths and F. A. Howe, An investigation of human brain tumor lipids by high-resolution magic angle spinning 1H MRS and histological analysis. NMR Biomed 21, 677-685 (2008).
131. J. E. Schmitz, M. I. Kettunen, D. E. Hu and K. M. Brindle, 1H MRS-visible lipids accumulate during apoptosis of lymphoma cells in vitro and in vivo. Magn Reson Med 54, 43-50 (2005). (Pubitemid 40898395)
132. S. Zoula, G. Herigault, A. Ziegler, R. Farion, M. Decorps and C. Remy, Correlation between the occurrence of 1H-MRS lipid signal, necrosis and lipid droplets during C6 rat glioma development. NMR Biomed 16, 199-212 (2003). (Pubitemid 37265323)
133. A. Knijn, A. Ferretti, P. J. Zhang, M. Giambenedetti, A. Molinari, S. Meschini, S. Pulciani and F. Podo, Lower levels of 1H MRSvisible mobile lipids in H-ras transformed tumorigenic fibroblasts with respect to their untransformed parental cells. Cell Mol Biol (Noisy-le-grand) 43, 691-701 (1997).
134. M. M. Mahon, N. M. deSouza, R. Dina, W. P. Soutter, G. A. McIndoe, A. D. Williams and I. J. Cox, Preinvasive and invasive cervical cancer: an ex vivo proton magic angle spinning magnetic resonance spectroscopy study. NMR Biomed 17, 144-153 (2004). (Pubitemid 38684563)
135. V. Righi, A. Mucci, L. Schenetti, M. R. Tosi, W. F. Grigioni, B. Corti, A. Bertaccini, A. Franceschelli, F. Sanguedolce, et al., Ex vivo HR-MAS magnetic resonance spectroscopy of normal and malignant human renal tissues. Anticancer Res 27, 3195-3204 (2007). (Pubitemid 47607542)
136. J. Griffitts, Y. Tesiram, G. E. Reid, D. Saunders, R. A. Floyd and R. A. Towner, In vivo MRS assessment of altered fatty acyl unsaturation in liver tumor formation of a TGF alpha/c-myc transgenic mouse model. J Lipid Res 50, 611-622 (2009).
137. V. Righi, A. Mucci, L. Schenetti, A. Bacci, R. Agati, M. Leonardi, R. Schiavina, G. Martorana, G. Liguori, et al., Identification of mobile lipids in human cancer tissues by ex vivo diffusion edited HR-MAS MRS. Oncol Rep 22, 1493-1496 (2009).
138. K. Stenman, J. B. Hauksson, G. Grobner, P. Stattin, A. Bergh and K. Riklund, Detection of polyunsaturated omega-6 fatty acid in human malignant prostate tissue by 1D and 2D high-resolution magic angle spinning NMR spectroscopy. MAGMA 22, 327-331 (2009).
139. J. R. Griffiths, D. J. McIntyre, F. A. Howe and M. Stubbs, Why are cancers acidic? A carrier-mediated diffusion model for H + transport in the interstitial fluid. Novartis Found Symp 240, 46-62; discussion 62-47, 152-153 (2001). (Pubitemid 33603779)
140. R. J. Gillies, Z. Liu and Z. Bhujwalla, 31P-MRS measurements of extracellular pH of tumors using 3-aminopropylphosphonate. Am J Physiol 267, C195-203 (1994).
141. R. van Sluis, Z. M. Bhujwalla, N. Raghunand, P. Ballesteros, J. Alvarez, S. Cerdan, J. P. Galons and R. J. Gillies, In vivo imaging of extracellular pH using 1H MRSI. Magn Reson Med 41, 743-750 (1999). (Pubitemid 29205721)
142. R. A. Gatenby and R. J. Gillies, Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4, 891-899 (2004). (Pubitemid 39472955)
143. A. Roos and W. F. Boron, Intracellular pH. Physiol Rev 61, 296-434 (1981).
144. W. H. Moolenaar, Effects of growth factors on intracellular pH regulation. Annu Rev Physiol 48, 363-376 (1986). (Pubitemid 16047621)
145. S. S. Ober and A. B. Pardee, Intracellular pH is increased after transformation of Chinese hamster embryo fibroblasts. Proc Natl Acad Sci USA 84, 2766-2770 (1987). (Pubitemid 17064725)
146. S. J. Reshkin, A. Bellizzi, S. Caldeira, V. Albarani, I. Malanchi, M. Poignee, M. Alunni-Fabbroni, V. Casavola and M. Tommasino, Na +H + exchanger-dependent intracellular alkalinization is an early event in malignant transformation and plays an essential role in the development of subsequent transformation-associated phenotypes. FASEB J 14, 2185-2197 (2000).
147. P. Swietach, R. D. Vaughan-Jones and A. L. Harris, Regulation of tumor pH and the role of carbonic anhydrase 9. Cancer Metastasis Rev 26, 299-310 (2007). (Pubitemid 47101667)
148. B. A. Webb, M. Chimenti, M. P. Jacobson and D. L. Barber, Dysregulated pH: a perfect storm for cancer progression. Nature Reviews Cancer 11, 671-677 (2011).
149. S. K. Parks, J. Chiche and J. Pouyssegur, pH control mechanisms of tumor survival and growth. Journal of Cellular Physiology 226, 299-308 (2011).
150. Y. Ihara, Y. Kihara, F. Hamano, K. Yanagida, Y. Morishita, A. Kunita, T. Yamori, M. Fukayama, H. Aburatani, et al., The G protein-coupled receptor T-cell death-associated gene 8 (TDAG8) facilitates tumor development by serving as an extracellular pH sensor. Proc Natl Acad Sci USA 107, 17309-17314 (2010).
151. D. Fukumura, L. Xu, Y. Chen, T. Gohongi, B. Seed and R. K. Jain, Hypoxia and acidosis independently up-regulate vascular endothelial growth factor transcription in brain tumors in vivo. Cancer Res 61, 6020-6024 (2001). (Pubitemid 32762531)
152. L. Xu, D. Fukumura and R. K. Jain, Acidic extracellular pH induces vascular endothelial growth factor (VEGF) in human glioblastoma cells via ERK1/2 MAPK signaling pathway: mechanism of low pH-induced VEGF. J Biol Chem 277, 11368-11374 (2002). (Pubitemid 34952903)
153. J. Rozhin, M. Sameni, G. Ziegler and B. F. Sloane, Pericellular pH affects distribution and secretion of cathepsin B in malignant cells. Cancer Res 54, 6517-6525 (1994).
154. I. F. Robey, B. K. Baggett, N. D. Kirkpatrick, D. J. Roe, J. Dosescu, B. F. Sloane, A. I. Hashim, D. L. Morse, N. Raghunand, et al., Bicarbonate increases tumor pH and inhibits spontaneous metastases. Cancer Res 69, 2260-2268 (2009).
155. M. Stubbs, Z. M. Bhujwalla, G. M. Tozer, L. M. Rodrigues, R. J. Maxwell, R. Morgan, F. A. Howe and J. R. Griffiths, An assessment of 31P MRS as a method of measuring pH in rat tumors. NMR Biomed 5, 351-359 (1992).
156. G. E. Soto, Z. Zhu, J. L. Evelhoch and J. J. Ackerman, Tumor 31P NMR pH measurements in vivo: a comparison of inorganic phosphate and intracellular 2-deoxyglucose-6-phosphate as pHnmr indicators in murine radiation-induced fibrosarcoma-1. Magn Reson Med 36, 698-704 (1996). (Pubitemid 26376708)
157. J. S. Taylor, D. B. Vigneron, J. Murphy-Boesch, S. J. Nelson, H. B. Kessler, L. Coia, W. Curran and T. R. Brown, Free magnesium levels in normal human brain and brain tumors: 31P chemicalshift imaging measurements at 1.5 T. Proc Natl Acad Sci USA 88, 6810-6814 (1991). (Pubitemid 21915039)
158. D. Maintz, W. Heindel, H. Kugel, R. Jaeger and K. J. Lackner, Phosphorus-31 MR spectroscopy of normal adult human brain and brain tumors. NMR Biomed 15, 18-27 (2002). (Pubitemid 34177164)
159. T. A. Cadoux-Hudson, M. J. Blackledge, B. Rajagopalan, D. J. Taylor and G. K. Radda, Human primary brain tumor metabolism in vivo: a phosphorus magnetic resonance spectroscopy study. Br J Cancer 60, 430-436 (1989). (Pubitemid 19227421)
160. K. Glunde and Z. M. Bhujwalla, Metabolic tumor imaging using magnetic resonance spectroscopy. Semin Oncol 38, 26-41 (2011).
161. S. He, R. P. Mason, S. Hunjan, V. D. Mehta, V. Arora, R. Katipally, P. V. Kulkarni and P. P. Antich, Development of novel 19F NMR pH indicators: synthesis and evaluation of a series of fluorinated vitamin B6 analogues. Bioorg Med Chem 6, 1631-1639 (1998). (Pubitemid 28446241)
162. R. P. Mason, Transmembrane pH gradients in vivo: measurements using fluorinated vitamin B6 derivatives. Curr Med Chem 6, 481-499 (1999). (Pubitemid 29256536)
163. A. S. Ojugo, P. M. McSheehy, D. J. McIntyre, C. McCoy, M. Stubbs, M. O. Leach, I. R. Judson and J. R. Griffiths, Measurement of the extracellular pH of solid tumors in mice by magnetic resonance spectroscopy: a comparison of exogenous (19)F and (31)P probes. NMR Biomed 12, 495-504 (1999). (Pubitemid 30090160)
164. R. J. Gillies and D. L. Morse, In vivo magnetic resonance spectroscopy in cancer. Annu Rev Biomed Eng 7, 287-326 (2005). (Pubitemid 41170190)
165. D. L. Rabenstein and A. A. Isab, Determination of the intracellular pH of intact erythrocytes by 1H NMR spectroscopy. Anal Biochem 121, 423-432 (1982). (Pubitemid 12052013)
166. S. Gil, P. Zaderenzo, F. Cruz, S. Cerdan and P. Ballesteros, Imidazol-1-ylalkanoic acids as extrinsic 1H NMR probes for the determination of intracellular pH, extracellular pH and cell volume. Bioorg Med Chem 2, 305-314 (1994).
167. M. L. Garcia-Martin, G. Herigault, C. Remy, R. Farion, P. Ballesteros, J. A. Coles, S. Cerdan and A. Ziegler, Mapping extracellular pH in rat brain gliomas in vivo by 1H magnetic resonance spectroscopic imaging: comparison with maps of metabolites. Cancer Res 61, 6524-6531 (2001). (Pubitemid 32783260)
168. P. Provent, M. Benito, B. Hiba, R. Farion, P. Lopez-Larrubia, P. Ballesteros, C. Remy, C. Segebarth, S. Cerdan, et al., Serial in vivo spectroscopic nuclear magnetic resonance imaging of lactate and extracellular pH in rat gliomas shows redistribution of protons away from sites of glycolysis. Cancer Res 67, 7638-7645 (2007). (Pubitemid 47281356)
169. D. W. Hoffman and R. W. Henkens, The rates of fast reactions of carbon dioxide and bicarbonate in human erythrocytes measured by carbon-13 NMR. Biochem Biophys Res Commun 143, 67-73 (1987). (Pubitemid 17030465)
170. C. Arus, Y. C. Chang and M. Barany, The separation of phosphocreatine from creatine, and pH determination in frog muscle by natural abundance 13C-NMR. Biochim Biophys Acta 844, 91-93 (1985). (Pubitemid 15157648)
171. F. A. Gallagher, M. I. Kettunen, S. E. Day, D. E. Hu, J. H. Ardenkjaer-Larsen, R. Zandt, P. R. Jensen, M. Karlsson, K. Golman, et al., Magnetic resonance imaging of pH in vivo using hyperpolarized 13C-labeled bicarbonate. Nature 453, 940-943 (2008). (Pubitemid 351832568)
172. E. O. Aboagye, R. J. Maxwell, M. R. Horsman, A. D. Lewis, P. Workman, M. Tracy and J. R. Griffiths, The relationship between tumor oxygenation determined by oxygen electrode measurements and magnetic resonance spectroscopy of the fluorinated 2-nitroimidazole SR-4554. Br J Cancer 77, 65-70 (1998). (Pubitemid 28029774)
173. B. M. Seddon, G. S. Payne, L. Simmons, R. Ruddle, R. Grimshaw, S. Tan, A. Turner, F. Raynaud, G. Halbert, et al., A phase I study of SR-4554 via intravenous administration for noninvasive investigation of tumor hypoxia by magnetic resonance spectroscopy in patients with malignancy. Clin Cancer Res 9, 5101-5112 (2003). (Pubitemid 37413558)
174. R. P. Mason, W. Rodbumrung and P. P. Antich, Hexafluorobenzene: a sensitive 19F NMR indicator of tumor oxygenation. NMR Biomed 9, 125-134 (1996). (Pubitemid 26368124)
175. B. J. Dardzinski and C. H. Sotak, Rapid tissue oxygen tension mapping using 19F inversion-recovery echo-planar imaging of perfluoro-15-crown-5-ether. Magn Reson Med 32, 88-97 (1994). (Pubitemid 24198559)
176. L. Bogin, M. Z. Papa, S. Polak-Charcon and H. Degani, TNFinduced modulations of phospholipid metabolism in human breast cancer cells. Biochim Biophys Acta 1392, 217-232 (1998). (Pubitemid 28287326)
177. N. W. Lutz, M. E. Tome and P. J. Cozzone, Early changes in glucose and phospholipid metabolism following apoptosis induction by IFN-gamma/TNF-alpha in HT-29 cells. FEBS Lett 544, 123-128 (2003). (Pubitemid 36628047)
178. J. I. Johnsen, M. Lindskog, F. Ponthan, I. Pettersen, L. Elfman, A. Orrego, B. Sveinbjornsson and P. Kogner, Cyclooxygenase-2 is expressed in neuroblastoma, and nonsteroidal anti-inflammatory drugs induce apoptosis and inhibit tumor growth in vivo. Cancer Res 64, 7210-7215 (2004). (Pubitemid 39372053)
179. M. Lindskog, C. Spenger, J. Jarvet, A. Graslund and P. Kogner, Predicting resistance or response to chemotherapy by proton magnetic resonance spectroscopy in neuroblastoma. J Natl Cancer Inst 96, 1457-1466 (2004). (Pubitemid 39429670)
180. M. Muruganandham, A. A. Alfieri, C. Matei, Y. Chen, G. Sukenick, I. Schemainda, M. Hasmann, L. B. Saltz and J. A. Koutcher, Metabolic signatures associated with a NAD synthesis inhibitor-induced tumor apoptosis identified by 1H-decoupled-31P magnetic resonance spectroscopy. Clin Cancer Res 11, 3503-3513 (2005). (Pubitemid 40627905)
181. J. E. Schmitz, M. I. Kettunen, D. E. Hu and K. M. Brindle, H-1 MRS-visible lipids accumulate during apoptosis of lymphoma cells in vitro and in vivo. Magn Reson Med 54, 43-50 (2005). (Pubitemid 40898395)
182. K. S. Opstad, B. A. Bell, J. R. Griffiths and F. A. Howe, Taurine: a potential marker of apoptosis in gliomas. Br J Cancer 100, 789-794 (2009).
183. T. Liimatainen, J. M. Hakumaki, R. A. Kauppinen and M. Ala-Korpela, Monitoring of gliomas in vivo by diffusion MRI and H-1 MRS during gene therapy-induced apoptosis: interrelationships between water diffusion and mobile lipids. Nmr in Biomedicine 22, 272-279 (2009).
184. A. C. Kuesel, G. R. Sutherland, W. Halliday and I. C. Smith, 1H MRS of high grade astrocytomas: mobile lipid accumulation in necrotic tissue. NMR Biomed 7, 149-155 (1994). (Pubitemid 2088968)
185. F. A. Howe and K. S. Opstad, H-1 MR spectroscopy of brain tumors and masses. NMR Biomed 16, 123-131 (2003). (Pubitemid 36950057)
186. A. R. Tate, J. Underwood, D. M. Acosta, M. Julia-Sape, C. Majos, A. Moreno-Torres, F. A. Howe, M. V. Graaf, V. Lefournier, et al., Development of a decision support system for diagnosis and grading of brain tumors using in vivo magnetic resonance single voxel spectra. NMR Biomed 19, 411-434 (2006). (Pubitemid 43997763)
187. M. Julià-Sapé, I. Coronel, C. Majó s, A. P. Candiota, M. Serrallonga, M. Cos, C. Aguilera, J. J. Acebes, J. R. Griffiths and C. Arús, Prospective diagnostic performance evaluation of single-voxel (1) H MRS for typing and grading of brain tumors. NMR Biomed (2011).
188. J. Kurhanewicz and D. B. Vigneron, Advances in MR spectroscopy of the prostate. Magn Reson Imaging Clin N Am 16, 697-710, ix-x (2008).
189. M. T. Nelson, L. I. Everson, M. Garwood, T. Emory and P. J. Bolan, MR Spectroscopy in the diagnosis and treatment of breast cancer. Semin Breast Dis 11, 100-105 (2008).
190. F. S. De Edelenyi, C. Rubin, F. Esteve, S. Grand, M. Decorps, V. Lefournier, J. F. Le Bas and C. Remy, A new approach for analyzing proton magnetic resonance spectroscopic images of brain tumors: nosologic images. Nature Medicine 6, 1287-1289 (2000).
191. T. C. Ng, W. T. Evanochko, R. N. Hiramoto, V. K. Ghanta, M. B. Lilly, A. J. Lawson, T. H. Corbett, J. R. Durant and J. D. Glickson, 31P NMR spectroscopy of in vivo tumors. Journal of Magnetic Resonance 49, 271-286 (1982).
192. G. M. Tozer, Z. M. Bhujwalla, J. R. Griffiths and R. J. Maxwell, Phosphorus-31 magnetic resonance spectroscopy and blood perfusion of the RIF-1 tumor following X-irradiation. International Journal of Radiation Oncology Biology and Physics 16, 155-164 (1989). (Pubitemid 19045348)
193. W. T. Evanochko, T. C. Ng, M. B. Lilly, A. J. Lawson, T. H. Corbett, J. R. Durant and J. D. Glickson, In vivo P31 NMR study of the metabolism of murine mammary 16/C adenocarcinoma and its response to chemotherapy, x-radiation, and hyperthermia. Proceedings of the National Academy of Sciences of the United States of America-Biological Sciences 80, 334-338 (1983). (Pubitemid 13174630)
194. J. A. Koutcher, P. Okunieff, L. Neuringer, H. Suit and T. Brady, Size dependent changes in tumor phosphate metabolism after radiation therapy as detected by P31 NMR spectroscopy. International Journal of Radiation Oncology Biology Physics 13, 1851-1855 (1987). (Pubitemid 18011341)
195. U. Mahmood, A. A. Alfieri, H. Thaler, D. Cowburn and J. A. Koutcher, Radiation dose-dependent changes in tumor metabolism measured by P31 nuclear magnetic resonance spectroscopy. Cancer Res 54, 4885-4891 (1994).
196. U. Mahmood, A. A. Alfieri, D. Ballon, F. Traganos and J. A. Koutcher, In-vitro and in-vivo P31 nuclear magnetic resonance measurements of metabolic changes post radiation. Cancer Res 55, 1248-1254 (1995).
197. P. E. Sijens, W. Bovee, D. Seijkens, G. Los and D. H. Rutgers, In vivo P31 nuclear magnetic resonance study of the response of a murine mammary tumor to different doses of gamma-radiation. Cancer Res 46, 1427-1432 (1986). (Pubitemid 16048291)
198. E. K. Rofstad, P. Demuth, B. M. Fenton, T. L. Ceckler and R. M. Sutherland, P31 NMR spectroscopy and HbO2 cryospectrophotometry in prediction of tumor radioresistance caused by hypoxia. International Journal of Radiation Oncology Biology Physics 16, 919-923 (1989). (Pubitemid 19154273)
199. K. K. Fu, M. F. Wendland, S. B. Iyer, K. N. Lam, H. Engeseth and T. L. James, Correlations between in vivo 31P NMR spectroscopy measurements, tumor size, hypoxic fraction and cell survival after radiotherapy. Int J Radiat Oncol Biol Phys 18, 1341-1350 (1990). (Pubitemid 20234145)
200. J. A. Koutcher, A. A. Alfieri, A. B. Kornblith, M. L. Devitt, D. Cowburn, D. Ballon and J. H. Kim, Changes in Radiation Sensitization Induced by Fluosol-DA as Measured by 31P Nuclear Magnetic Resonance Spectroscopy. Cancer Res 50, 7252-7256 (1990).
201. W. Semmler, G. Gademann, P. Bachertbaumann, H. J. Zabel, W. J. Lorenz and G. Vankaick, Monitoring human tumor response to therapy by means of P31 MR spectroscopy. Radiology 166, 533-539 (1988). (Pubitemid 18030771)
202. T. C. Ng, S. Grundfest, S. Vijayakumar, N. J. Baldwin, A. W. Majors, I. Karalis, T. F. Meaney, K. H. Shin, F. J. Thomas and R. Tubbs, Therapeutic response of breast carcinoma monitored by P31 MRS in situ. Magn Reson Med 10, 125-134 (1989). (Pubitemid 19107972)
203. M. O. Leach, M. Verrill, J. Glaholm, T. A. D. Smith, D. J. Collins, G. S. Payne, J. C. Sharp, S. M. Ronen, V. R. McCready, et al., Measurements of human breast cancer using magnetic resonance spectroscopy: a review of clinical measurements and a report of localized P-31 measurements of response to treatment. NMR Biomed 11, 314-340 (1998). (Pubitemid 28547368)
204. D. M. Prescott, H. C. Charles, H. D. Sostman, R. K. Dodge, D. E. Thrall, R. L. Page, J. A. Tucker, J. M. Harrelson, K. A. Leopold, et al., Therapy monitoring in human and canine soft-tissue sarcomas using magnetic resonance imaging and spectroscopy. International Journal of Radiation Oncology Biology Physics 28, 415-423 (1994). (Pubitemid 24020526)
205. S. K. Szigety, P. S. Allen, D. Huyserwierenga and R. C. Urtasun, The effect of radiation on normal human CNS as detected by NMR spectroscopy. International Journal of Radiation Oncology Biology Physics 25, 695-701 (1993). (Pubitemid 23099265)
206. D. Brandsma, L. Stalpers, W. Taal, P. Sminia and M. van den Bent, Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncology 9, 453-461 (2008). (Pubitemid 351597795)
207. J. D. Rabinov, P. L. Lee, F. G. Barker, D. N. Louis, G. R. Harsh, G. R. Cosgrove, E. A. Chiocca, A. F. Thornton, J. S. Loeffler, et al., In vivo 3-T MR spectroscopy in the distinction of recurrent glioma versus radiation effects: Initial experience. Radiology 225, 871-879 (2002). (Pubitemid 35387129)
208. M. C. Preul, R. Leblanc, Z. Caramanos, R. Kasrai, S. Narayanan and D. L. Arnold, Magnetic resonance spectroscopy guided brain tumor resection: Differentiation between recurrent glioma and radiation change in two diagnostically difficult cases. Canadian Journal of Neurological Sciences 25, 13-22 (1998). (Pubitemid 28210154)
209. H. P. Schlemmer, P. Bachert, K. K. Herfarth, I. Zuna, J. Debus and G. van Kaick, Proton MR spectroscopic evaluation of suspicious brain lesions after stereotactic radiotherapy. American Journal of Neuroradiology 22, 1316-1324 (2001). (Pubitemid 32734804)
210. M. A. Heesters, R. L. Kamman, E. L. Mooyaart and K. G. Go, Localized proton spectroscopy of inoperable brain gliomas. Response to radiation therapy. J Neurooncol 17, 27-35 (1993). (Pubitemid 24006746)
211. A. Bizzi, B. Movsas, G. Tedeschi, C. L. Phillips, P. Okunieff, J. R. Alger and G. Dichiro, Response of non-Hodgkin lymphoma to radiation therapy-early and long-term assessment with H1 MR spectroscopic imaging. Radiology 194, 271-276 (1995).
212. T. Usenius, J. P. Usenius, M. Tenhunen, P. Vainio, R. Johansson, S. Soimakallio and R. Kauppinen, Radiation-induced changes in human brain metabolites as studied by H1 nuclear magnetic resonance spectroscopy in vivo. International Journal of Radiation Oncology Biology Physics 33, 719-724 (1995).
213. J. S. Taylor, J. W. Langston, W. E. Reddick, P. B. Kingsley, R. J. Ogg, M. H. Pui, L. E. Kun, J. J. Jenkins, G. Chen, et al., Clinical value of proton magnetic resonance spectroscopy for differentiating recurrent or residual brain tumor from delayed cerebral necrosis. International Journal of Radiation Oncology Biology Physics 36, 1251-1261 (1996). (Pubitemid 27014515)
214. L. L. Wald, S. J. Nelson, M. R. Ray, S. E. Noworolski, R. G. Henry, S. L. Huhn, S. Chang, M. D. Prados, P. K. Sneed, et al., Serial proton magnetic resonance spectroscopy imaging of glioblastoma multiforme after brachytherapy. Journal of Neurosurgery 87, 525-534 (1997). (Pubitemid 27430398)
215. F. Esteve, C. Rubin, S. Grand, H. Kolodie and J. F. Le Bas, Transient metabolic changes observed with proton MR spectroscopy in normal human brain after radiation therapy. International Journal of Radiation Oncology Biology Physics 40, 279-286 (1998). (Pubitemid 28114369)
216. S. M. Waldrop, P. C. Davis, C. A. Padgett, M. B. Shapiro and R. Morris, Treatment of brain tumors in children is associated with abnormal MR spectroscopic ratios in brain tissue remote from the tumor site. American Journal of Neuroradiology 19, 963-970 (1998). (Pubitemid 30415789)
217. J. A. Lazareff, R. K. Gupta and J. Alger, Variation of posttreatment H-MRSI choline signal intensity in pediatric gliomas. Journal of Neuro-Oncology 41, 291-298 (1999). (Pubitemid 29209818)
218. Y. L. Chan, D. K. W. Yeung, S. F. Leung and G. Cao, Proton magnetic resonance spectroscopy of late delayed radiationinduced injury of the brain. Journal of Magnetic Resonance Imaging 10, 130-137 (1999). (Pubitemid 29362426)
219. V. F. H. Chong, H. Rumpel, Y. F. Fan and S. K. Mukherji, Temporal lobe changes following radiation therapy: imaging and proton MR spectroscopic findings. European Radiology 11, 317-324 (2001). (Pubitemid 32755455)
220. H. P. Schlemmer, P. Bachert, M. Henze, R. Buslei, K. K. Herfarth, J. Debus and G. van Kaick, Differentiation of radiation necrosis from tumor progression using proton magnetic resonance spectroscopy. Neuroradiology 44, 216-222 (2002). (Pubitemid 36075911)
221. E. E. Graves, S. J. Nelson, D. B. Vigneron, L. Verhey, M. McDermott, D. Larson, S. Chang, M. D. Prados and W. P. Dillon, Serial proton MR spectroscopic imaging of recurrent malignant gliomas after gamma knife radiosurgery. AJNR Am J Neuroradiol 22, 613-624 (2001). (Pubitemid 32318685)
222. C. Dowling, A. W. Bollen, S. M. Noworolski, M. W. McDermott, N. M. Barbaro, M. R. Day, R. G. Henry, S. M. Chang, W. P. Dillon, et al., Preoperative proton MR spectroscopic imaging of brain tumors: correlation with histopathologic analysis of resection specimens.[see comment]. Ajnr: American Journal of Neuroradiology 22, 604-612 (2001). (Pubitemid 32318684)
223. J. P. Rock, D. Hearshen, L. Scarpace, D. Croteau, J. Gutierrez, J. L. Fisher, M. L. Rosenblum and T. Mikkelsen, Correlations between magnetic resonance spectroscopy and image-guided histopathology, with special attention to radiation necrosis. Neurosurgery 51, 912-919 (2002).
224. R. Tarnawski, M. Sokol, P. Pieniazek, B. Maciejewski, J. Walecki, L. Miszczyk and T. Krupska, H-1-MRS in vivo predicts the early treatment outcome of postoperative radiotherapy for malignant gliomas. International Journal of Radiation Oncology Biology Physics 52, 1271-1276 (2002). (Pubitemid 34302880)
225. P. Weybright, P. C. Sundgren, P. Maly, D. G. Hassan, B. Nan, S. Rohrer and L. Junck, Differentiation between brain tumor recurrence and radiation injury using MR spectroscopy. American Journal of Roentgenology 185, 1471-1476 (2005).
226. A. Pirzkall, T. R. McKnight, E. E. Graves, M. P. Carol, P. K. Sneed, W. W. Wara, S. J. Nelson, L. J. Verhey and D. A. Larson, MR-spectroscopy guided target delineation for high-grade gliomas. International Journal of Radiation Oncology Biology Physics 50, 915-928 (2001). (Pubitemid 32594834)
227. A. Pirzkall, S. J. Nelson, T. R. McKnight, M. M. Takahashi, X. J. Li, E. E. Graves, L. J. Verhey, W. W. Wara, D. A. Larson and P. K. Sneed, Metabolic imaging of low-grade gliomas with threedimensional magnetic resonance spectroscopy. International Journal of Radiation Oncology Biology Physics 53, 1254-1264 (2002). (Pubitemid 34787862)
228. A. Pirzkall, X. J. Li, J. M. Oh, S. Chang, M. S. Berger, D. A. Larson, L. J. Verhey, W. P. Dillon and S. J. Nelson, 3D MRSI for resected high-grade gliomas before RT: Tumor extent according to metabolic activity in relation to MRI. International Journal of Radiation Oncology Biology Physics 59, 126-137 (2004). (Pubitemid 38501516)
229. A. Laprie, A. Pirzkall, D. A. Haas-Kogan, S. Cha, A. Banerjee, T. P. Le, Y. Lu, S. Nelson and T. R. McKnight, Longitudinal multivoxel MR spectroscopy study of pediatric diffuse brainstem gliomas treated with radiotherapy. International Journal of Radiation Oncology Biology Physics 62, 20-31 (2005). (Pubitemid 40591919)
230. F. V. Coakley, H. S. Teh, A. Qayyum, M. G. Swanson, Y. Lu, M. Roach, B. Pickett, K. Shinohara, D. B. Vigneron and J. Kurhanewicz, Endorectal MR imaging MR spectroscopic imaging for locally recurrent prostate cancer after external beam radiation therapy: Preliminary experience. Radiology 233, 441-448 (2004). (Pubitemid 39423803)
231. J. Pouliot, Y. Kim, E. Lessard, I. C. Hsu, D. B. Vigneron and J. Kurhanewicz, Inverse planning for HDR prostate brachytherapy used to boost dominant intraprostatic lesions defined by magnetic resonance spectroscopy imaging. International Journal of Radiation Oncology Biology Physics 59, 1196-1207 (2004). (Pubitemid 38834315)
232. J. A. Jung, F. V. Coakley, D. B. Vigneron, M. G. Swanson, A. Qayyum, V. Weinberg, K. D. Jones, P. R. Carroll and J. Kurhanewicz, Prostate depiction at endorectal MR spectroscopic imaging: Investigation of a standardized evaluation system. Radiology 233, 701-708 (2004).
233. B. Pickett, R. K. Ten Haken, J. Kurhanewicz, A. Qayyum, K. Shinohara, B. Fein and M. Roach, Time to metabolic atrophy after permanent prostate seed implantation based on magnetic resonance spectroscopic imaging. International Journal of Radiation Oncology Biology Physics 59, 665-673 (2004). (Pubitemid 38748731)
234. B. Pickett, J. Kurhanewicz, F. Coakley, K. Shinohara, B. Fein and M. Roach, Use of MRI and spectroscopy in evaluation of external beam radiotherapy for prostate cancer. International Journal of Radiation Oncology Biology Physics 60, 1047-1055 (2004). (Pubitemid 39440788)
235. D. Pucar, A. Shukla-Dave, H. Hricak, C. S. Moskowitz, K. Kuroiwa, S. Olgac, L. E. Ebora, P. T. Scardino, J. A. Koutcher and K. L. Zakian, Prostate cancer: Correlation of MR Imaging and MR spectroscopy with pathologic findings after radiation therapy-Initial experience. Radiology 236, 545-553 (2005). (Pubitemid 41023438)
236. C. Menard, I. C. P. Smith, R. L. Somorjai, L. Leboldus, R. Patel, C. Littman, S. J. Robertson and T. Bezabeh, Magnetic resonance spectroscopy of the malignant prostate gland after radiotherapy: A histopathologic study of diagnostic validity. International Journal of Radiation Oncology Biology Physics 50, 317-323 (2001). (Pubitemid 32472261)
237. A. D. King, D. K. W. Yeung, K. H. Yu, F. K. F. Mo, K. S. Bhatia, G. M. K. Tse, A. C. Vlantis, J. K. T. Wong, C. W. Hu and A. T. Ahuja, Pre-treatment and Early Intratreatment Prediction of Clinicopathologic Response of Head and Neck Cancer to Chemoradiotherapy Using H-1-MRS. Journal of Magnetic Resonance Imaging 32, 199-203 (2010).
238. Z. M. Bhujwalla and J. D. Glickson, Detection of tumor response to radiation therapy by in vivo proton MR spectroscopy. International Journal of Radiation Oncology Biology Physics 36, 635-639 (1996). (Pubitemid 26404306)
239. D. C. Shungu and J. D. Glickson, Band-selective spin echoes for in vivo localized 1H NMR spectroscopy. Magn Reson Med 32, 277-284 (1994). (Pubitemid 24274905)
240. E. O. Aboagye, Z. M. Bhujwalla, Q. H. He and J. D. Glickson, Evaluation of lactate as a H-1 nuclear magnetic resonance spectroscopy index for noninvasive prediction and early detection of tumor response to radiation therapy in EMT6 tumors. Radiation Research 150, 38-42 (1998). (Pubitemid 28285623)
241. V. Quennet, A. Yaromina, D. Zips, A. Rosner, S. Walenta, M. Baumann and W. Mueller-Klieser, Tumor lactate content predicts for response to fractionated irradiation of human squamous cell carcinomas in nude mice. Radiotherapy and Oncology 81, 130-135 (2006). (Pubitemid 44780779)
242. J. P. Dyke, K. L. Zakian, W. M. Spees, C. Matei, Y. C. Chen, M. L. Mao, D. C. Shungu and J. A. Koutcher, Metabolic response of the CWR22 prostate tumor xenograft after 20 Gy of radiation studied by H-1 spectroscopic imaging. Clin Cancer Res 9, 4529-4536 (2003). (Pubitemid 37248412)
243. S. E. Day, M. I. Kettunen, M. K. Cherukuri, J. B. Mitchell, M. J. Lizak, H. D. Morris, S. Matsumoto, A. P. Koretsky and K. M. Brindle, Detecting Response of Rat C6 Glioma Tumors to Radiotherapy Using Hyperpolarized 1-(13)C Pyruvate and (13)C Magnetic Resonance Spectroscopic Imaging. Magn Reson Med 65, 557-563 (2011).
244. W. Semmler, G. Gademann, P. Schlag, P. Bachertbaumann, H. J. Zabel, W. J. Lorenz and G. Vonkaick, Impact of hyperthermic regional perfusion therapy on cell metabolism of malignant melanoma monitored by P31 MR spectroscopy. Magnetic Resonance Imaging 6, 335-340 (1988).
245. C. Kettelhack, M. V. Wickede, T. Vogl, U. Schneider and P. Hohenberger, (31)phosphorus-magnetic resonance spectroscopy to assess histologic tumor response noninvasively after isolated limb perfusion for soft tissue tumors. Cancer 94, 1557-1564 (2002). (Pubitemid 34212651)
246. A. Shukla-Dave, H. Poptani, L. A. Loevner, A. Mancuso, H. Serrai, D. I. Rosenthal, A. M. Kilger, D. S. Nelson, K. L. Zakian, et al., Prediction of treatment response of head and neck cancers with P-31 MR spectroscopy from pre-treatment relative phosphomonoester levels. Academic Radiology 9, 688-694 (2002). (Pubitemid 34568804)
247. E. Proietti, G. Carpinelli, M. Divito, F. Belardelli, I. Gresser and F. Podo, P31-nuclear magnetic-resonance analysis of interferoninduced alterations of phospholipid metabolites in interferonsensitive and interferon-resistant Friend-leukemia cell tumors in mice. Cancer Res 46, 2849-2857 (1986). (Pubitemid 16074293)
248. C. Allavena, J. L. Guerquin-Kern and J. M. Lhoste, Follow-up by 31P NMR spectroscopy of the energy metabolism of malignant tumor in rats during treatment. Radiother Oncol 21, 48-52 (1991).
249. D. A. Beauregard, P. E. Thelwall, D. J. Chaplin, S. A. Hill, G. E. Adams and K. M. Brindle, Magnetic resonance imaging and spectroscopy of combretastatin A(4) prodrug-induced disruption of tumor perfusion and energetic status. British Journal of Cancer 77, 1761-1767 (1998). (Pubitemid 28254609)
250. D. A. Beauregard, R. B. Pedley, S. A. Hill and K. M. Brindle, Differential sensitivity of two adenocarcinoma xenografts to the anti-vascular drugs combretastatin A4 phosphate and 5,6-dimethylxanthenone-4-acetic acid, assessed using MRI and MRS. NMR Biomed 15, 99-105 (2002). (Pubitemid 34213399)
251. L. D. McPhail, Y. L. Chung, B. Madhu, S. Clark, J. R. Griffiths, L. R. Kelland and S. P. Robinson, Tumor dose response to the vascular disrupting agent, 5,6-dimethylxanthenone-4-acetic acid, using in vivo magnetic resonance spectroscopy. Clin Cancer Res 11, 3705-3713 (2005).
252. J. A. Koutcher, M. Motwani, K. L. Zakian, X. K. Li, C. Matei, J. P. Dyke, D. Ballon, H. H. Yoo and G. K. Schwartz, The in vivo effect of bryostatin-1 on paclitaxel-induced tumor growth, mitotic entry, and blood flow. Clin Cancer Res 6, 1498-1507 (2000). (Pubitemid 30226239)
253. G. R. Silberhumer, K. Zakian, S. Malhotra, P. Brader, M. Gonen, J. Koutcher and Y. Fong, Relationship between P-31 metabolites and oncolytic viral therapy sensitivity in human colorectal cancer xenografts. British Journal of Surgery 96, 809-816 (2009).
254. J. Klawitter, D. J. Kominsky, J. L. Brown, U. Christians, D. Leibfritz, J. V. Melo, S. G. Eckhardt and N. J. Serkova, Metabolic characteristics of imatinib resistance in chronic myeloid leukaemia cells. British Journal of Pharmacology 158, 588-600 (2009).
255. J. A. Koutcher, A. A. Alfieri, C. Matei, K. L. Meyer, J. C. Street and D. S. Martin, Effect of 6-aminonicotinamide on the pentose phosphate pathway: P-31 NMR and tumor growth delay studies. Magn Reson Med 36, 887-892 (1996). (Pubitemid 26396816)
256. N. M. S. Al-Saffar, L. E. Jackson, F. I. Raynaud, P. A. Clarke, A. R. de Molina, J. C. Lacal, P. Workman and M. O. Leach, The Phosphoinositide 3-Kinase Inhibitor PI-103 Downregulates Choline Kinase a Leading to Phosphocholine and Total Choline Decrease Detected by Magnetic Resonance Spectroscopy. Cancer Res 70, 5507-5517 (2010).
257. Y. L. Chung, H. Troy, U. Banerji, L. E. Jackson, M. I. Walton, M. Stubbs, J. R. Griffiths, I. R. Judson, M. O. Leach, et al., Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino,17-demethoxygeldanamycin (17AAG) in human colon cancer models. Journal of the National Cancer Institute 95, 1624-1633 (2003). (Pubitemid 37455930)
258. A. H. Brandes, C. S. Ward and S. M. Ronen, 17-allyamino-17- demethoxygeldanamycin treatment results in a magnetic resonance spectroscopy-detectable elevation in choline-containing metabolites associated with increased expression of choline transporter SLC44A1 and phospholipase A2. Breast Cancer Research 12, R84 (2010).
259. Y. L. Chung, H. Troy, R. Kristeleit, W. Aherne, E. Jackson, P. Atadja, J. R. Griffiths, I. R. Judson, P. Workman, et al., Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of a novel histone deacetylase inhibitor, LAQ824, in human colon carcinoma cells and xenografts. Neoplasia 10, 303-313 (2008). (Pubitemid 351483570)
260. M. Sankaranarayanapillai, W. P. Tong, D. S. Maxwell, A. Pal, J. H. Pang, W. G. Bornmann, J. G. Gelovani and S. M. Ronen, Detection of histone deacetylase inhibition by noninvasive magnetic resonance spectroscopy. Molecular Cancer Therapeutics 5, 1325-1334 (2006). (Pubitemid 43881326)
261. M. Sterin, J. S. Cohen, Y. Mardor, E. Berman and I. Ringel, Levels of phospholipid metabolites in breast cancer cells treated with antimitotic drugs: A P-31-magnetic resonance spectroscopy study. Cancer Res 61, 7536-7543 (2001). (Pubitemid 32995045)
262. L. M. Rodrigues, R. J. Maxwell, P. M. McSheehy, C. R. Pinkerton, S. P. Robinson, M. Stubbs and J. R. Griffiths, In vivo detection of ifosfamide by 31P-MRS in rat tumors: increased uptake and cytotoxicity induced by carbogen breathing in GH3 prolactinomas. Br J Cancer 75, 62-68 (1997). (Pubitemid 27007274)
263. L. M. Rodrigues, S. P. Robinson, P. M. J. McSheehy, M. Stubbs and J. R. Griffiths, Enhanced uptake of ifosfamide into GH3 prolactinomas with hypercapnic hyperoxic gases monitored in vivo by P-31 MRS. Neoplasia 4, 539-543 (2002). (Pubitemid 35417078)
264. G. S. Payne, C. R. Pinkerton, E. Bouffet and M. O. Leach, Initial measurements of ifosfamide and cyclophosphamide in patients using P-31 MRS: Pulse-and-acquire, decoupling, and polarization transfer. Magn Reson Med 44, 180-184 (2000). (Pubitemid 30614775)
265. L. Mancini, G. S. Payne, A. S. K. Dzik-Jurasz and M. O. Leach, Ifosfamide pharmacokinetics and hepatobiliary uptake in vivo investigated using single-and double-resonance P-31 MRS. Magn Reson Med 50, 249-255 (2003). (Pubitemid 36950843)
266. G. S. Payne, A. S. K. Dzik-Jurasz, L. Mancini, B. Nutley, F. Raynaud and M. O. Leach, Identification of biliary metabolites of ifosfamide using P-31 magnetic resonance spectroscopy and mass spectrometry. Cancer Chemotherapy and Pharmacology 56, 409-414 (2005). (Pubitemid 41095404)
267. S. T. Fricke, O. Rodriguez, J. VanMeter, L. E. Dettin, M. Casimiro, C. D. Chien, T. Newell, K. Johnson, L. Ileva, et al., In vivo magnetic resonance volumetric and spectroscopic analysis of mouse prostate Cancer Models. The Prostate 66, 708-717 (2006).
268. D. C. Shungu, Z. M. Bhujwalla, J. P. Wehrle and J. D. Glickson, 1H NMR
269. Y. Mardor, O. Kaplan, M. Sterin, J. Ruiz-Cabello, E. Ash, Y. Roth, I. Ringel and J. S. Cohen, Noninvasive real-time monitoring of intracellular cancer cell metabolism and response to lonidamine treatment using diffusion weighted proton magnetic resonance spectroscopy. Cancer Res 60, 5179-5186 (2000).
270. P. C. M. van Zijl, C. T. W. Moonen, P. Faustino, J. Pekar, O. Kaplan and J. S. Cohen, Complete separation of intracellular and extracellular information in NMR spectra of perfused cells by diffusion-weighted spectroscopy. Proceedings of the National Academy of Sciences of the United States of America 88, 3228-3232 (1991). (Pubitemid 21916593)
271. K. Natarajan, N. Mori, D. Artemov and Z. M. Bhujwalla, Exposure of human breast cancer cells to the anti-inflammatory agent indomethacin alters choline phospholipid metabolites and Nm23 expression. Neoplasia 4, 409-416 (2002). (Pubitemid 34976956)
272. M. Q. Huang, D. S. Nelson, S. Pickup, H. Qiao, E. J. Delikatny, H. Poptani and J. D. Glickson, In vivo monitoring response to chemotherapy of human diffuse large B-cell lymphoma xenografts in SCID mice by 1H and 31P MRS. Acad Radiol 14, 1531-1539 (2007). (Pubitemid 350116639)
273. S. C. Lee, M. Q. Huang, D. S. Nelson, S. Pickup, S. Wehrli, O. Adegbola, H. Poptani, E. J. Delikatny and J. D. Glickson, In vivo MRS markers of response to CHOP chemotherapy in the WSUDLCL2 human diffuse large B-cell lymphoma xenograft. NMR Biomed 21, 723-733 (2008).
274. A. J. Schwarz, N. R. Maisey, D. J. Collins, D. Cunningham, R. Huddart and M. O. Leach, Early in vivo detection of metabolic response: a pilot study of 1H MR spectroscopy in extracranial lymphoma and germ cell tumors. 75, 959-966 (2002).
275. J. R. Griffiths, A. R. Tate, F. A. Howe, M. Stubbs and G. Multi Inst, Magnetic Resonance Spectroscopy of cancer-practicalities of multi-centre trials and early results in non-Hodgkin's lymphoma. European Journal of Cancer 38, 2085-2093 (2002). (Pubitemid 35223246)
276. S. C. Lee, E. J. Delikatny, H. Poptani, S. Pickup and J. D. Glickson, In vivo H-1 MRS of WSU-DLCL2 human non-Hodgkin's lymphoma xenografts: response to rituximab and rituximab plus CHOP. NMR Biomed 22, 259-265 (2009).
277. H. M. Baek, J. H. Chen, K. Nie, H. J. Yu, S. Bahri, R. S. Mehta, O. Nalcioglu and M. Y. Su, Predicting pathologic response to neoadjuvant chemotherapy in breast cancer by using MR imaging and quantitative 1H MR spectroscopy. Radiology 251, 653-662 (2009).
278. M. Tozaki, M. Sakamoto, Y. Oyama, T. O'Uchi, N. Kawano, T. Suzuki, N. Yamashiro, S. Ozaki, N. Sakamoto, et al., Monitoring of early response to neoadjuvant chemotherapy in breast cancer with H-1 MR spectroscopy: Comparison to sequential 2-18F-fluorodeoxyglucose positron emission tomography. Journal of Magnetic Resonance Imaging 28, 420-427 (2008).
279. U. Sharma, H. M. Baek, M. Y. Su and N. R. Jagannathan, In vivo (1)H MRS in the assessment of the therapeutic response of breast cancer patients. NMR Biomed 24, 700-711 (2011).
280. C. Balmaceda, D. Critchell, X. L. Mao, K. Cheung, S. Pannullo, R. L. DeLaPaz and D. C. Shungu, Multisection H-1 magnetic resonance spectroscopic imaging assessment of glioma response to chemotherapy. Journal of Neuro-Oncology 76, 185-191 (2006). (Pubitemid 43125747)
281. J. P. Dyke, P. C. Sanelli, H. U. Voss, J. V. Serventi, P. E. Stieg, T. H. Schwartz, D. Ballon, D. C. Shungu and S. C. Pannullo, Monitoring the effects of BCNU chemotherapy Wafers (Gliadel (R)) in glioblastoma multiforme with proton magnetic resonance spectroscopic imaging at 3.0 Tesla. Journal of Neuro-Oncology 82, 103-110 (2007).
282. T. Sankar, Z. Caramanos, R. Assina, J. G. Villemure, R. Leblanc, A. Langleben, D. L. Arnold and M. C. Preul, Prospective serial proton MR spectroscopic assessment of response to tamoxifen for recurrent malignant glioma. Journal of Neuro-Oncology 90, 63-76 (2008).
283. M. C. Preul, Z. Caramanos, J. G. Villemure, G. Shenouda, R. LeBlanc, A. Langleben and D. L. Arnold, Using proton magnetic resonance spectroscopic imaging to predict in vivo the response of recurrent malignant gliomas to tamoxifen chemotherapy. Neurosurgery 46, 306-318 (2000). (Pubitemid 30094467)
284. N. R. Jagannathan, M. Singh, V. Govindaraju, P. Raghunathan, O. Coshic, P. K. Julka and G. K. Rath, Volume localized in vivo proton MR spectroscopy of breast carcinoma: variation of waterfat ratio in patients receiving chemotherapy. NMR Biomed 11, 414-422 (1998). (Pubitemid 29031851)
285. D. J. Manton, A. Chaturvedi, A. Hubbard, M. J. Lind, M. Lowry, A. Maraveyas, M. D. Pickles, D. J. Tozer and L. W. Turnbull, Neoadjuvant chemotherapy in breast cancer: early response prediction with quantitative MR imaging and spectroscopy. Br J Cancer 94, 427-435 (2006). (Pubitemid 43237566)
286. P. E. G. Kristjansen, B. Quistorff, M. Spangthomsen and H. H. Hansen, Intratumoral pharmacokinetic analysis by F19 magnetic resonance spectroscopy and cytostatic in-vivo activity of gemcitabine (DFDC) in 2 small-cell lung-cancer xenografts. Annals of Oncology 4, 157-160 (1993). (Pubitemid 23061318)
287. A. W. Blackstock, H. Lightfoot, L. D. Case, J. E. Tepper, S. K. Mukherji, B. S. Mitchell, S. G. Swarts and S. M. Hess, Tumor uptake and elimination of 20,20-difluoro-20-deoxycytidine (gemcitabine) after deoxycytidine kinase gene transfer: correlation with in vivo tumor response. Clin Cancer Res 7, 3263-3268 (2001). (Pubitemid 32963852)
288. G. O. Cron, N. Beghein, R. Ansiaux, P. Martinive, O. Feron and B. Gallez, F-19 NMR in vivo spectroscopy reflects the effectiveness of perfusion-enhancing vascular modifiers for improving gemcitabine chemotherapy. Magn Reson Med 59, 19-27 (2008).
289. K. P. Olive, M. A. Jacobetz, C. J. Davidson, A. Gopinathan, D. McIntyre, D. Honess, B. Madhu, M. A. Goldgraben, M. E. Caldwell, et al., Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer. Science 324, 1457-1461 (2009).
290. H. Pinedo and G. Peters, Fluorouracil: biochemistry and pharmacology. J Clin Oncol 6, 1653-1664 (1988).
291. P. M. J. McSheehy, M. T. Seymour, A. S. E. Ojugo, L. M. Rodrigues, M. O. Leach, I. R. Judson and J. R. Griffiths, A pharmacokinetic and pharmacodynamic study in vivo of human HT29 tumors using F-19 and P-31 magnetic resonance spectroscopy. European Journal of Cancer 33, 2418-2427 (1997). (Pubitemid 28129187)
292. N. W. Lutz, B. Naser-Hijazi, S. Koroma, M. R. Berger and W. E. Hull, Fluoropyrimidine chemotherapy in a rat model: comparison of fluorouracil metabolite profiles determined by high-field F-19-NMR spectroscopy of tissues ex vivo with therapy response and toxicity for locoregional vs systemic infusion protocols. NMR Biomed 17, 101-131 (2004). (Pubitemid 38684561)
293. Y. Doi, T. Shimmura, H. Kuribayashi, Y. Tanaka and Y. Kanazawa, Quantitative 19F imaging of nmol-level F-nucleotides/-sides from 5-FU with T2 mapping in mice at 9.4T. Magn Reson Med 62, 1129-1139 (2009).
294. A. S. K. Dzik-Jurasz, D. J. Collins, M. O. Leach and I. J. Rowland, Gallbladder localization of 19F MRS catabolite signals in patients receiving bolus and protracted venous infusional 5-fluorouracil. Magn Reson Med 44, 516-520 (2000).
295. M.-C. Malet-Martino, R. Martino, A. Lopez, J.-P. Béteille, M. Bon, J. Bernadou and J.-P. Armand, New approach to metabolism of 50-deoxy-5-fluorouridine in humans with fluo-rine-19 NMR. Cancer Chemotherapy and Pharmacology 13, 31-35 (1984). (Pubitemid 14120902)
296. A. N. Stevens, P. G. Morris, R. A. Iles, P. W. Sheldon and J. R. Griffiths, 5-fluorouracil metabolism monitored in vivo by 19F NMR. Br J Cancer 50, 113-117 (1984). (Pubitemid 14092653)
297. W. Wolf, M. J. Albright, M. S. Silver, H. Weber, U. Reichardt and R. Sauer, Fluorine-19 NMR spectroscopic studies of the metabolism of 5-fluorouracil in the liver of patients undergoing chemotherapy. Magn Reson Imaging 5, 165-169 (1987). (Pubitemid 17133352)
298. W. Wolf, C. A. Presant, K. L. Servis, A. El-Tahtawy, M. J. Albright, P. B. Barker, Ring R, III, D. Atkinson, R. Ong, et al., Tumor Trapping of 5-Fluorouracil: In vivo 19F NMR Spectroscopic Pharmacokinetics in Tumor-Bearing Humans and Rabbits. Proceedings of the National Academy of Sciences 87, 492-496 (1990).
299. C. A. Presant, W. Wolf, V. Waluch, C. Wiseman, P. Kennedy, D. Blayney and R. R. Brechner, Association of intratumoral pharmacokinetics of fluorouracil with clinical response. The Lancet 343, 1184-1187 (1994). (Pubitemid 24147552)
300. W. Wolf, V. Waluch and C. A. Presant, Non-invasive F-19-NMRS of 5-fluorouracil in pharmacokinetics and pharmacodynamic studies. NMR Biomed 11, 380-387 (1998). (Pubitemid 28547373)
301. W. Wolf, C. A. Presant and V. Waluch, 19F-MRS studies of fluorinated drugs in humans. Advanced Drug Delivery Reviews 41, 55-74 (2000).
302. C. A. Presant, W. Wolf, V. Waluch, C. L. Wiseman, I. Weitz and J. Shani, Enhancement of Fluorouracil Uptake in Human Colorectal and Gastric Cancers by Interferon or by High-Dose Methotrexate: An In Vivo Human Study Using Noninvasive 19FMagnetic Resonance Spectroscopy. Journal of Clinical Oncology 18, 255-000 (2000).
303. C. A. Presant, J. Jacobson, W. Wolf, V. Waluch, I. C. Weitz and J. S. Macdonald, Does Leucovorin Alter the Intratumoral Pharmacokinetics of 5-Fluorouracil (5-FU)? A Southwest Oncology Group Study. Investigational New Drugs 20, 369-376 (2002). (Pubitemid 35252778)
304. A. El-Tahtawy and W. Wolf, In Vivo Measurements of Intratumoral Metabolism, Modulation, and Pharmacokinetics of 5-Fluorouracil, Using 19F Nuclear Magnetic Resonance Spectroscopy. Cancer Res 51, 5806-5812 (1991).
305. J.-L. Guerquin-Kern, F. Leteurtre, A. Croisy and J.-M. Lhoste, pH Dependence of 5-Fluorouracil Uptake Observed by in Vivo 31P and 19F Nuclear Magnetic Resonance Spectroscopy. Cancer Res 51, 5770-5773 (1991).
306. L. E. Gerweck, J. G. Rhee, A. K. Jason, C. W. Song and M. Urano, Regulation of pH in Murine Tumor and Muscle. Radiation Research 126, 206-209 (1991).
307. A. S. E. Ojugo, P. M. J. McSheehy, M. Stubbs, G. Alder, C. L. Bashford, R. J. Maxwell, M. O. Leach, I. R. Judson and J. R. Griffiths, Influence of pH on the uptake of 5-fluorouracil into isolated tumor cells. Br J Cancer 77, 873-879 (1998). (Pubitemid 28101772)
308. P. M. J. McSheehy, H. Troy, L. R. Kelland, I. R. Judson, M. O. Leach and J. R. Griffiths, Increased tumor extracellular pH induced by Bafilomycin A(1) inhibits tumor growth and mitosis in vivo and alters 5-fluorouracil pharmacokinetics. European Journal of Cancer 39, 532-540 (2003). (Pubitemid 36173699)
309. L. P. Lemaire, P. M. J. McSheehy and J. R. Griffiths, Pretreatment energy status of primary rat tumors as the best predictor of response to 5-fluorouracil chemotherapy: a magnetic resonance spectroscopy study in vivo. Cancer Chemotherapy and Pharmacology 42, 201-209 (1998). (Pubitemid 28329196)
310. W. Semmler, P. Bachert-Baumann, F. Gückel, F. Ermark, P. Schlag, W. J. Lorenz and G. van Kaick, Real-time follow-up of 5-fluorouracil metabolism in the liver of tumor patients by means of F-19 MR spectroscopy. Radiology 174, 141-145 (1990). (Pubitemid 20017098)
311. M. P. N. Findlay, M. O. Leach, D. Cunningham, D. J. Collins, G. S. Payne, J. Glaholm, J. L. Mansi and V. R. McCready, The noninvasive monitoring of low dose, infusional 5-fluorouracil and its modulation by interferon-a using in vivo 19F magnetic resonance spectroscopy in patients with colorectal cancer: A pilot study. Annals of Oncology 4, 597-602 (1993). (Pubitemid 23257559)
312. H. P. Schlemmer, P. Bachert, W. Semmler, P. Hohenberger, P. Schlag, W. J. Lorenz and G. van Kaick, Drug monitoring of 5-fluorouracil: in vivo 19F NMR study during 5-FU chemotherapy in patients with metastases of colorectal adenocarcinoma. Magn Reson Imaging 12, 497-511 (1994).
313. C. W. Li, W. G. Negendank, K. A. Padavic-Shaller, P. J. O'Dwyer, J. Murphy-Boesch and T. R. Brown, Quantitation of 5-fluorouracil catabolism in human liver in vivo by threedimensional localized 19F magnetic resonance spectroscopy. Clin Cancer Res 2, 339-345 (1996).
314. J. Murphy-Boesch, C.-W. Li, L. He, K. A. Padavic-Shaller, W. Negendank and T. R. Brown, Proton-decoupled 19F spectroscopy of 5-FU catabolites in human liver. Magn Reson Med 37, 321-326 (1997). (Pubitemid 27107953)
315. C. W. Li and O. Gonen, Simultaneous 3D NMR spectroscopy of fluorine and phosphorus in human liver during 5-fluorouracil chemotherapy. Magn Reson Med 35, 841-847 (1996). (Pubitemid 26172619)
316. D. W. Klomp, H. W. Van Laarhoven, A. P. Kentgens and A. Heerschap, Optimization of localized 19F magnetic resonance spectroscopy for the detection of fluorinated drugs in the human liver. Magn Reson Med 50, 303-308 (2003). (Pubitemid 36950849)
317. H. W. M. van Laarhoven, D. W. J. Klomp, M. Rijpkema, Y. L. P. Kamm, D. J. T. Wagener, J. O. Barentsz, C. J. A. Punt and A. Heerschap, Prediction of chemotherapeutic response of colorectal liver metastases with dynamic gadolinium-DTPA-enhanced MRI and localized F-19 MRS pharmacokinetic studies of 5-fluorouracil. NMR Biomed 20, 128-140 (2007). (Pubitemid 46470935)
318. P. S. Tofts, G. Brix, D. L. Buckley, J. L. Evelhoch, E. Henderson, M. Knopp, H. B. W. Larsson, T. Y. Lee, N. A. Mayr, et al., Estimating kinetic parameters from dynamic contrast-enhanced T-1-weighted MRI of a diffusable tracer: Standardized quantities and symbols. Journal of Magnetic Resonance Imaging 10, 223-232 (1999). (Pubitemid 29463104)
319. J. R. Griffiths, D. J. O. McIntyre, F. A. Howe, P. M. J. McSheehy, A. S. E. Ojugo, L. M. Rodrigues, P. Wadsworth, N. M. Price, F. Lofts, et al., Issues of normal tissue toxicity in patient and animal studies-Effect of carbogen breathing in rats after 5-fluorouracil treatment. Acta Oncologica 40, 609-614 (2001). (Pubitemid 32912439)
320. D. J. O. McIntyre, F. A. Howe, C. Ladroue, F. Lofts, M. Stubbs and J. R. Griffiths, Can localised 19F magnetic resonance spectroscopy pharmacokinetics of 5FU in colorectal metastases predict clinical response? Cancer Chemotherapy and Pharmacology 68, 29-36 (2011).
321. P. M. J. McSheehy, S. P. Robinson, A. S. E. Ojugo, E. O. Aboagye, M. B. Cannell, M. O. Leach, I. R. Judson and J. R. Griffiths, Carbogen breathing increases 5-fluorouracil uptake and cytotoxicity in hypoxic murine RIF-1 tumors: A magnetic resonance study in vivo. Cancer Res 58, 1185-1194 (1998). (Pubitemid 28183207)
322. P. M. J. McSheehy, R. E. Port, L. M. Rodrigues, S. P. Robinson, M. Stubbs, K. van der Borns, G. J. Peters, I. R. Judson, M. O. Leach and J. R. Griffiths, Investigations in vivo of the effects of carbogen breathing on 5-fluorouracil pharmacokinetics and physiology of solid rodent tumours. Cancer Chemotherapy and Pharmacology 55, 117-128 (2005). (Pubitemid 40110054)
323. Y. J. L. Kamm, A. Heerschap and D. J. T. Wagener, Effect of carbogen breathing on the pharmacodynamics of 5-fluorouracil in a murine colon carcinoma. European Journal of Cancer 36, 1180-1186 (2000). (Pubitemid 30330917)
324. Y. J. L. Kamm, G. J. Peters, W. E. Hull, C. J. A. Punt and A. Heerschap, Correlation between 5-fluorouracil metabolism and treatment response in two variants of C26 murine colon carcinoma. Br J Cancer 89, 754-762 (2003). (Pubitemid 37076185)
325. H. W. M. van Laarhoven, G. Gambarota, J. Lok, M. Lammens, Y. L. M. Kamm, T. Wagener, C. J. A. Punt, A. J. van der Kogelz and A. Heerschap, Carbogen breathing differentially enhances blood plasma volume and 5-fluorouracil uptake in two murine colon tumor models with a distinct vascular structure. Neoplasia 8, 477-487 (2006). (Pubitemid 44035332)
326. P. M. McSheehy, M. J. Prior and J. R. Griffiths, Prediction of 5-fluorouracil cytotoxicity towards the Walker carcinosarcoma using peak integrals of fluoronucleotides measured by MRS in vivo. Br J Cancer 60, 303-309 (1989). (Pubitemid 19227396)
327. P. McSheehy, M. Prior and J. Griffiths, Enhanced 5-fluorouracil cytotoxicity and elevated 5-fluoronucleotides in the rat Walker carcinosarcoma following methotrexate pre-treatment: a 19FMRS study in vivo. Br J Cancer 65, 369-375 (1992).
328. M. J. Prior, R. J. Maxwell and J. R. Griffiths, In vivo 19F NMR spectroscopy of the antimetabolite 5-fluorouracil and its analogues. An assessment of drug metabolism. Biochemical Pharmacology 39, 857-863 (1990). (Pubitemid 20060681)
329. S. K. Holland, A. M. Bergman, Y. Zhao, E. R. Adams and G. Pizzorno, 19F NMR monitoring of in vivo tumor metabolism after biochemical modulation of 5-fluorouracil by the uridine phosphorylase inhibitor 5-benzylacyclouridine. Magn Reson Med 38, 907-916 (1997). (Pubitemid 27508634)
330. H. W. M. van Laarhoven, D. W. J. Klomp, Y. J. L. Kamm, C. J. A. Punt and A. Heerschap, In Vivo Monitoring of Capecitabine Metabolism in Human Liver by 19Fluorine Magnetic Resonance Spectroscopy at 1.5 and 3 Tesla Field Strength. Cancer Res 63, 7609-7612 (2003). (Pubitemid 37466682)
331. D. Klomp, H. van Laarhoven, T. Scheenen, Y. Kamm and A. Heerschap, Quantitative 19F MR spectroscopy at 3 T to detect heterogeneous capecitabine metabolism in human liver. NMR Biomed 20, 485-492 (2007). (Pubitemid 47272368)
332. Y.-L. Chung, H. Troy, I. R. Judson, R. Leek, M. O. Leach, M. Stubbs, A. L. Harris and J. R. Griffiths, Noninvasive Measurements of Capecitabine Metabolism in Bladder Tumors Overexpressing Thymidine Phosphorylase by Fluorine-19 Magnetic Resonance Spectroscopy. Clin Cancer Res 10, 3863-3870 (2004). (Pubitemid 38697622)
333. H. Poptani, N. Bansal, W. T. Jenkins, D. Blessington, A. Mancuso, D. S. Nelson, M. Feldman, E. J. Delikatny, B. Chance and J. D. Glickson, Cyclophosphamide treatment modifies tumor oxygenation and glycolytic rates of RIF-1 tumors: 13C magnetic resonance spectroscopy, Eppendorf electrode, and redox scanning. Cancer Res 63, 8813-8820 (2003). (Pubitemid 38064060)
334. D. Rivenzon-Segal, S. Boldin-Adamsky, D. Seger, R. Seger and H. Degani, Glycolysis and glucose transporter 1 as markers of response to hormonal therapy in breast cancer. International Journal of Cancer 107, 177-182 (2003). (Pubitemid 37152894)
335. T. H. Witney, M. I. Kettunen, S. E. Day, D. E. Hu, A. A. Neves, F. A. Gallagher, S. M. Fulton and K. M. Brindle, A Comparison between Radiolabeled Fluorodeoxyglucose Uptake and Hyperpolarized C-13-Labeled Pyruvate Utilization as Methods for Detecting Tumor Response to Treatment. Neoplasia 11, 574-U588 (2009).
336. P. Seth, A. Grant, J. Tang, E. Vinogradov, X. Wang, R. Lenkinski and V. P. Sukhatme, On-target inhibition of tumor fermentative glycolysis as visualized by hyperpolarized pyruvate. Neoplasia 13, 60-71 (2011).
337. I. Park, R. Bok, T. Ozawa, J. J. Phillips, C. D. James, D. B. Vigneron, S. M. Ronen and S. J. Nelson, Detection of Early Response to Temozolomide Treatment in Brain Tumors Using Hyperpolarized (13)C MR Metabolic Imaging. Journal of Magnetic Resonance Imaging 33, 1284-1290 (2011).
338. F. A. Gallagher, M. I. Kettunen, D. E. Hu, P. R. Jensen, R. Zandt, M. Karlsson, A. Gisselsson, S. K. Nelson, T. H. Witney, et al., Production of hyperpolarized 1,4-(13)C(2) malate from 1,4-(13)C(2) fumarate is a marker of cell necrosis and treatment response in tumors. Proceedings of the National Academy of Sciences of the United States of America 106, 19801-19806 (2009).
339. S. E. Bohndiek, M. I. Kettunen, D. E. Hu, T. H. Witney, B. W. C. Kennedy, F. A. Gallagher and K. M. Brindle, Detection of Tumor Response to a Vascular Disrupting Agent by Hyperpolarized C-13 Magnetic Resonance Spectroscopy. Molecular Cancer Therapeutics 9, 3278-3288 (2010).
340. T. H. Witney, M. I. Kettunen, D. E. Hu, F. A. Gallagher, S. E. Bohndiek, R. Napolitano and K. M. Brindle, Detecting treatment response in a model of human breast adenocarcinoma using hyperpolarised 1-C-13 pyruvate and 1,4-C-13(2) fumarate. British Journal of Cancer 103, 1400-1406 (2010).
341. C. S. Ward, H. S. Venkatesh, M. M. Chaumeil, A. H. Brandes, M. Vancriekinge, H. Dafni, S. Sukumar, S. J. Nelson, D. B. Vigneron, et al., Noninvasive detection of target modulation following phosphatidylinositol 3-kinase inhibition using hyperpolarized 13C magnetic resonance spectroscopy. Cancer Res 70, 1296-1305 (2010).